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ABSTRACT 
KARMINDER GILL:  Correcting for non-adherence in a randomized study of hip 
protectors to prevent fractures  
(Under the direction of Stephen Cole) 
 
Between October 2002 and October 2004 the Hip Impact Protection Project 
(HIP PRO) cluster randomized 1042 nursing home residents to wear hip protectors 
on either the left or right hip; residents were followed for 676 person-years of 
observation. The intent-to-treat (ITT) incidence rate ratio, comparing protected to 
unprotected hips, was 1.23 (95% confidence limit (CL): 0.65, 2.34); overall 
adherence was 74%.  When non-adherence is substantial an ITT analysis estimates 
the effectiveness of treatment in a mixed population comprised of both compliers 
and non-compliers and, therefore, under-estimates the etiologic effect of treatment 
to the extent that the study population is comprised of non-compliers.   
Because of the problems inherent to ITT analyses of studies with non-trivial 
amounts of non-adherence, there have been calls to supplement the ITT effect 
estimate with adherence corrected effect estimates. Three relatively new methods in 
the epidemiology literature correct for non-adherence in randomized studies, and 
provide unbiased effect estimates: marginal structural models (using inverse 
probability-of-censoring weights (IPCWs)), structural nested models, and 
instrumental variable analysis.  
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We employed IPCWs to correct for non-adherence in the HIP PRO study 
under an assumption that we had measured and correctly modeled all important joint 
determinants of adherence and hip fracture, and obtained a hazard ratio of 0.55 
(95% CL: 0.13, 2.40).  Under a structural nested modeling approach, we employed a 
rank-preserving structural failure time model to identify the survival difference that 
would have been observed had all participants adhered to their assigned treatment.  
The factor by which time to a hip fracture was expanded under continuous exposure 
to hip protectors was 2.41 (95% CL: 0.31, 18.7), assuming a Weibull distribution for 
time to hip fracture. The estimated hazard ratio under constant exposure was 0.46 
(95% CL: 0.07, 2.84).  
Using data from the HIP PRO study, we found apparent differences in results 
between the ITT analysis and analyses correcting for non-adherence.  We do not 
take the adherence corrected results as a complete reversal of the prior analysis; 
rather, we see these results as supplementing the ITT analysis.  
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CHAPTER 1 
CRITICAL REVIEW OF THE LITERATURE 
 
GENERAL BACKGROUND 
 
A hip fracture is any break in the proximal portion of the femur, including the 
head of femur or neck of femur (cervical fractures), and the trochanteric region of the 
femur (trochanteric fractures) (see Figure 1.1).  A third type of hip fracture, the sub-
trochanteric fracture, is located anatomically distal to the lesser trochanter of the 
femur, and occurs much less often than the other two types.1 Such fractures often 
result in a disruption of the blood flow to the femoral head, and cause debilitating 
pain and nerve impairment.  The sciatic nerve, one of the major nerves of the body, 
innervating the muscles of the leg and foot, is often impacted. 
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Figure 1.1. The Hip Joint2 
 
The number of annual hip fractures has increased substantially over the past 
25 years, owing mostly to the aging of the U.S. population.3 These hip fractures 
result in a substantial cost to the individual whose hip is fractured, as well as to 
society.4  The long-term consequences, in terms of death and disability, are 
substantial.5-8   Consequently, much effort has been devoted to interventions that 
might potentially reduce the incidence of hip fractures.  Exercise programs to 
improve balance and strength9-11, medications, hormonal treatment, and vitamin 
supplementation programs to reduce the resorption of bone4, 7, 12-14, environmental 
modification interventions, or some combination of these approaches5, 11, 15 have all 
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noted significant but small reductions in the incidence of hip fractures.  The relatively 
small reductions in the incidence of hip fractures resulting from these interventions 
prompted investigators to examine the potential benefit of hip protectors.  Hip 
protectors are designed to prevent hip fractures by either absorbing the energy from 
a fall directly on the hip, or dispersing the energy of the fall to the soft tissue 
surrounding the hip.  In this dissertation we will be particularly interested in 
evaluating the effect of the hip protector which was used in the Hip Impact Protection 
Project (HIP PRO).16  Before embarking on an evaluation of the effectiveness of this 
hip protector, however, we review in greater detail the epidemiology of hip fractures, 
the risk factors for hip fractures, and a systematic review of previous randomized 
studies of hip protectors. 
 
EPIDEMIOLOGY OF HIP FRACTURES 
 
From 1993 to 2003, the number of hip fracture hospitalizations increased 19% 
in the United States, from 261,000 to 309,500,3 and projections by researchers 
suggest that, with the aging of the population, the total number of hip fractures could 
increase to 512,000 by 2040.4  However, because the size of the elderly population 
has been growing faster than predicted, and because hip fracture rates rise 
dramatically with age, the number of elderly experiencing a hip fracture in the United 
Sates could total 840,000 by 2040.17  Worldwide projections paint an even bleaker 
picture, with the total number of hip fractures forecast to increase from 1.26 million in 
1990 to 4.5 million by 2050, assuming no increases in age-specific hip fracture 
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rates.18  If the increase in age-specific hip fracture rates seen over the past two 
decades is taken into account, the worldwide annual number of hip fractures could 
rise to 6.26 million by 2050.19  The number of hip fractures is expected to increase 
most dramatically in Asia, where aging populations are expected to contribute more 
than two million hip fractures annually by 2050.18  
 The cost of hip fractures to society is substantial, with hip fractures 
accounting for more than 20% of the usage of orthopedic beds in several 
countries.19  In the United States, hip fractures account for more than half of all 
osteoporosis-related hospital admissions among women 45 years old and over.20  
The direct costs for inpatient and outpatient medical services and nursing home care 
are expected to increase the total annual cost of hip fractures in the United States (in 
1984 dollars) from approximately $7.2 billion to $16 billion by 2040.  If a 3% or 5% 
rate of inflation is taken into account, the total annual costs of hip fractures could 
reach $82 billion or $240 billion, respectively.4  The loss in quality of life for those 
impacted by hip fractures adds another important dimension to the costs of hip 
fractures. 
 The consequences of a hip fracture can be severe.  Studies from across the 
globe reveal surprisingly consistent outcomes for individuals suffering hip fractures.  
One UK study found that 15% of patients presenting with a fractured neck of the 
femur die in the hospital and 33% are dead within one year.21  In the United States, 
one year survival after hip fracture has ranged from 12-25% in the general 
population.6  In nursing homes, where the incidence of first hip fracture can be as 
high as 44 (95% confidence interval: 34-54) per 1,000 person years, mortality rates 
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are even higher, at 39% for one year.7  Age is an important predictor of death.  
Individuals 80 years and older have a mortality rate that is eight times greater than 
persons 60 and under.22  Most of the increase in mortality attributed to hip fracture 
occurs within the first six months after hip fracture.8  While overall life expectancy is 
reduced by 6 years in both men and women,23 men generally experience markedly 
higher mortality from hip fractures when compared to women.24  
 Hip fractures result not only in high mortality rates, but, for those who survive 
a hip fracture, can also have severe long-term consequences.  Many individuals 
never regain their pre-fracture level of physical functioning: most have significant 
reduction in their ability to function in daily life and in their ability to walk.25  Mossey 
et al noted that while 80% of elderly individuals could walk independently before 
their hip fracture, only 21% could walk independently after the hip fracture.26  Fear of 
falling, loss of confidence, and functional deterioration all contributed to the reduction 
in mobility.  Up to 66% will ultimately have impaired mobility and 27-50% will have 
continued post-operative pain.27-28  Long term follow-up results suggest that almost 
half of all patients with hip fracture will have become more dependent and 20-25% 
will have been referred to a nursing home.29  Individuals with cognitive impairment, 
in particular, find it difficult to recover from hip fracture surgery.30  
 
RISK FACTORS FOR HIP FRACTURES 
 
 A hip fracture usually occurs as a result of the interaction of two unique 
processes:  a fall event resulting in direct impact to the proximal portion of the femur 
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and an underlying weakness in the bone caused by osteoporosis.6 Each of these 
processes has underlying risk factors that have been reasonably well studied.  For 
example, demographics, anthropometric factors, and co-morbidities have been 
shown to impact bone health.  With falls, much of the literature has focused on the 
first phase of the fall (i.e., where an individual’s normal protective responses fail).  
Environmental factors, such as loose carpeting and icy sidewalks, as well as 
individual co-morbidities, such as postural hypertension, have been shown to 
contribute to the first phase of a fall.  However, a fall can be conceptualized as 
occurring in four stages:  (1) an instability phase that results in a loss of balance due 
to host and environmental factors; (2) a descent phase; (3) an impact phase (i.e., the 
impact of the fall occurs near the hip, the soft tissue around the hip demonstrates 
poor energy absorption/distribution, and reduced bone strength fails to withstand the 
energy transmitted to the proximal femur), and (4) a post-impact phase during which 
the subject comes to rest.10, 31-33  More recent interest in the later three stages of a 
fall have shown that the direction of the fall, the subcutaneous fat covering the 
greater trochanter, and other factors play an important role in the incidence of hip 
fractures.  In short, there are a number of host and environmental risk factors that 
contribute to a fall, and, ultimately, result in a hip fracture.   
 
Demographics 
 
 The incidence of hip fractures rises exponentially with increasing age.4, 25, 34  
The increase in age-specific incidence rates is often explained by muscular 
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weakness, gait and balance disorders, functional impairment, cognitive impairment, 
and the side effects of drugs.6  In addition, secular increases in height (and perhaps 
hip axis length), and changes in environmental factors such as the hardness of 
surfaces on which falls occur, have been proposed as reasons for the increase in 
age-specific incidence rates.34  While the increase in age-specific incidence rates 
occurs in both men and women, the incidence of hip fractures is approximately two 
times higher in women, when compared to men.25, 34  A study by Jacobsen et al in 
the U.S. showed age-adjusted incidence rates in white males and females as 4.3 
and 8.1 per 1,000 per year, respectively.24  A woman 60 years of age with a median 
life expectancy of 81 years has an estimated residual lifetime risk of hip fracture of 
14%, while a man 60 years of age with a median life expectancy of 77 years has an 
estimated fracture risk of 6%.35  This relationship changes only in the very old, when 
men and women have nearly the same risk of hip fracture.35  In both men and 
women, the age-adjusted incidence of hip fracture is lower in nonwhites than whites, 
and among nonwhites, the incidence is lower in Asian races than in black races.36  
The lifetime risk of hip fracture is about 6% in black women, much lower than the risk 
in white women, but similar to white men.37  Higher bone mass and increased 
obesity may contribute to lower incidence rates in blacks and Hispanics, and shorter 
hip axis length in Asians, black, and Hispanics may also play a role in the lower 
incidence of hip fractures in these populations. 24-25 
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Anthropometric Factors 
 
 Using almost any measure of body size, including weight, fat mass, percent 
body fat, and body mass index (BMI), the risk of hip fracture in those with a smaller 
body size is higher than in those with a larger body size.  For example, Ensrud et 
al38 found that older women with smaller body size had an approximately two-fold 
increased risk of hip fracture when compared with those with larger body size, 
whereas risks of hip fracture in women with average and larger body sizes were not 
significantly different from each other.  The incidence rate of hip fracture was 9.35 
per 1,000 years in women in the lowest quartile of total weight, compared with 4.63 
per 1,000 years in the highest quartile of body weight.  Another study showed that a 
20% gain in weight between age 25 and old age was associated with a 40% 
reduction in risk of hip fracture.39  
There are several explanations for why a larger body size might be protective 
against hip fractures.  In women, the conversion of androstenedione to the more 
active estone in adipose tissue is the major source of estrogen (a hormone that is 
protective against hip fracture) in post-menopausal women.  Most evidence 
suggests that greater estrogen acts primarily to reduce bone resorption in post-
menopausal women.40  In men and women, weight increases the transmitted 
gravitational forces on bone, stimulating bone re-modeling, and, ultimately, resulting 
in higher bone mineral density.  Also, low body weight can be a marker of poor 
health, itself a risk factor for falls and fractures.  Finally, increased weight leads to 
more soft tissue overlying the greater trochanter, which reduces the forces applied to 
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the proximal femur in a fall.25, 38, 41  Lauritzen et al found a difference between cases 
and controls in the thickness of the subcutaneous tissue covering the hip: women 
with hip fractures had an average 22 mm thick soft tissue cover of the hip compared 
with 32 mm in healthy women.29, 42  Bolstering the importance of the protective effect 
of soft tissue covering the hip are biomechanical experiments, which show that a 
porcine soft tissue layer of 29 mm could absorb 60% more energy than a 20 mm 
thick layer of the same material. 
Height, independent of weight, has been demonstrated as an increased risk 
for hip fracture.25, 43  Height is strongly correlated with hip axis length, which is 
associated with an increased risk of hip fracture.  After adjustment for age, each 
standard deviation increase in hip axis length appears to double the risk of hip 
fracture.44  
 
Co-morbidities 
 
 Studies have consistently demonstrated that impairment of gait and balance, 
and lower and upper body strength are associated with an increased risk of falls and 
hip fractures.45-47  Muscle weakness, lower limb dysfunction, skeletal impairments, 
difficulty or dependence in activities of daily living, and use of walking aids (a marker 
of neuromuscular impairment) have been associated with increased hip fracture 
risk.48-50  Individuals who have difficulty with gait and balance also tend to have lower 
reaction times, are less likely to break a fall with an outstretched arm, and are more 
likely to fall in a position that results in impact on the hip.43  Especially among the 
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elderly, who have stiffer, less coordinated, and more dangerous gait than younger 
people, and who have poorer posture control, body-orienting reflexes, and muscle 
strength, the ability to avoid a fall is reduced.43, 51  Among elderly individuals with 
Parkinson’s disease, who have particular difficulty with gait and balance, the 
reported relative risk of hip fracture can be as high as 10 or more, when compared to 
individuals who do not have Parkinson’s disease.50, 52  
 Individuals with cognitive impairment are at higher risk of hip fracture than 
individuals with no dementia.49  In general, patients with Alzheimer’s disease 
demonstrate a greater risk of falling and higher rate of serious injury than those 
without Alzheimer’s disease.  Buchner and Larson53 noted that the risk of hip 
fractures among people with Alzheimer’s disease was three times higher than in 
those without hip fractures.  In another 4-year study, 36% of 44 subjects diagnosed 
with Alzheimer’s disease fell and sustained five hip fractures; non-demented controls 
had four falls and only one hip fracture.54  Individuals with dementia have a harder 
time recognizing environmental hazards and have poorer neuromuscular control 
than individuals without dementia.25   
 The presence of osteoporosis at the hip is defined as a bone mineral density 
measurement that is 2.5 standard deviations or more below the young healthy 
population.  A substantial proportion of the elderly population has some degree of 
osteoporosis and many fall into the high-risk range.  About 25% of white women in 
the United States who are age 65 or older have hip bone mass that is more than 2.5 
standard deviations below the mean value of young normal women, and they have 
an approximately five-fold greater risk of hip fracture than women whose bone mass 
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is above that level.55  Over a lifetime, bone density of the femoral neck declines an 
estimated 58% and 39% in women and men, respectively.56  For the 50-year old 
woman with osteoporosis, the lifetime risk of hip fracture is greater than 60%.34  
Osteoporosis does contribute to hip fractures.  Data suggest that 70% of hip 
fractures are at least partially attributable to osteoporosis.57  However, there is not a 
great difference in bone mineral density between individuals experiencing hip 
fractures and age-matched controls; indeed, there is a substantial overlap in bone 
density values between these two groups.  Most studies suggest that elderly men 
and women have lost sufficient bone for the hip to fracture in case of impact during 
an unprotected fall.29  
 Those elderly individuals who are malnourished or undernourished are at 
particular risk of osteoporosis and hip fracture.  Deficiencies in micro-nutrients, such 
as calcium, vitamin D, and vitamin K, have been strongly implicated in the 
pathogenesis of hip fracture in the osteoporotic elderly, because these 
micronutrients play a major role in the control of bone remodeling and bone 
integrity.58-60  In addition, deficiency in macronutrients such as proteins has been 
associated with lower bone mineral density (BMD) of the femoral neck.61  Poor 
nutrition contributes to an increased risk of hip fracture not only through its impact on 
the bone, but also due to the fact that it increases the propensity to fall by impairing 
movement coordination and reducing muscle strength, and reduces the protective 
layer of soft tissue padding over the greater trochanter.12  
 A history of prior fragility fractures, particularly prior hip fractures, is 
associated with an increased risk of subsequent hip fractures.  This increased risk 
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may be due to risks that are similar to the prior fractures (e.g., osteoporosis, family 
history), or may be due to the fact that individuals with prior fractures may be more 
vulnerable or accident-prone for some time after the index fracture.  The later 
hypothesis is supported by the fact that, after a prior fracture, the greatest risk of hip 
fracture is in the one year time period immediately after the index fracture.29  Women 
have an increased risk of hip fracture after either a fracture of the knee or a fracture 
of the ankle62-63, and women who reported that their mothers had had a hip fracture 
had twice the risk of hip fracture of women without this family history.39  For all 
individuals, previous fractures of the ribs and of the lumbar spine result in a 3-4 
times increased risk of subsequent hip fractures.56  People who sustain one hip 
fracture are 2-10 times more likely to fracture their second hip, when compared to 
controls.  
 
Environmental Factors 
 
 Three fourths of femoral neck fractures occur in the home and approximately 
two thirds of these are due to a fall precipitated by an environmental hazard.  
Factors associated with falls at home include unstable furniture and appliances, 
creaky stairs with poor rails, change in surface level, throw rugs and frayed carpets, 
poor lighting, low beds and toilets, pets, and objects on the floor.51, 64  There appears 
to be no seasonal variation in hip fractures, with most hip fractures occurring 
indoors. 
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The Institutional Setting 
 
 The risk of hip fractures in elderly residents who reside in institutional settings 
are substantially greater than those living in private homes.  Butler et al65 found that 
the risk of hip fracture (after adjustment for age and sex) was 10.5 times greater for 
those living in institutions.  The incidence rate of hip fracture among the 
institutionalized population is high, such that one in every 25 individuals who live in 
an institution is likely to sustain a hip fracture annually.  The difference in risks is 
greater for the ‘younger old,’ those aged 60 to 69, with differences in risk declining 
with age.65  Another study by Baudoin66 et al noted that, for patients living in 
community homes and who were aged 60-69, the risk of hip fracture was 15 times 
greater than the risk of individuals living at home.  Norton et al67 noted somewhat 
lower risks (age- and gender-adjusted OR=3.8 (3.0,4.8)) of hip fracture in individuals 
living in institutions, when compared to individuals living in private homes.  
 
Falls 
 
 Falls have been identified as the proximal cause of a hip fracture in the 
elderly in 90% of cases.  The elderly are especially prone to falls, with the major 
causes of falls in the elderly being:  accidents, syncope (i.e., sudden loss of 
consciousness), drop attacks (i.e., sudden falls without loss of consciousness), 
orthostatic hypertension, dizziness/vertigo, neurology dysfunction, vision impairment, 
and drugs.51, 64  Underlying disease symptoms, such as cardiac dysrhythmia, 
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orthostatic hypertension, and cerebrovascular disease all contribute to an increased 
risk of falls in the elderly.  Many medications to treat diseases in the elderly have 
been associated with an increased risk of falls and subsequent hip fracture: anti-
psychotics (RR=2.0), long-acting hypnotics (RR=1.8), tricyclic anti-depressants 
(RR=1.9), and opiod analgesics (codeine and/or propoxyphene) (RR=1.6) were 
associated with an increased risk of hip fractures.68-70  Over-medication, in particular, 
has been associated with an increased risk of falls and hip fracture.  
 A prior fall, in the 9-12 months before the hip fracture, doubles the risk of hip 
fracture.  Fall incidence in the elderly increases with age, with 25% of elderly in their 
sixties falling at least once annually, and 55% of elderly in their nineties falling at 
least once.71  Among those living in the community, 33% of individuals aged 65 and 
older experience one or more falls during the year.72  In institutional settings, with 
populations that are in poorer health, the annual incidence of falls is about 
1,500/1,000 resident-years.  The rate of falling among those living in institutions 
(excluding acute hospitals) has been estimated at 50%, with 10-25% suffering 
severe consequences.73  
 Early research focused almost entirely on the instability phase of the fall, that 
interaction of host and environmental factors that result in a loss of balance.  More 
recent research has started to focus on the orientation of the fall and the point of 
impact, which also play an important role in the etiology of hip fractures.  Falling 
sideways is associated with an increased risk of hip fractures, while hitting the knee, 
hitting the hand, and falling backward are inversely associated with the risk of hip 
fracture, and falling backward is not associated with the occurrence of a hip 
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fractures.43  Greenspan et al11, in a study of community-dwelling elderly noted that 
sideways falls resulted in an increased risk of hip fracture when compared to a fall in 
any other direction (OR=5.7 (2.3,14.0)).  When the point of impact after the fall is 
directly on the hip, the odds ratio for hip fracture in institutionalized elderly 
populations has been documented to range from 5.7 to 21.7.74  Another study of 
elderly women living in the community who had previously fallen at least once noted 
a 33-fold increased risk of hip fracture when individuals landed on the hip, side of the 
leg, or buttocks.43  Parkkari et al33, using a fresh subcutaneous hematoma on the 
greater trochanter of the proximal femur as evidence of falling on the hip, in a case-
control study, found a hematoma in 56% of hip fracture patients, but in only 6% of 
controls.  In addition, biomechanical studies indicate that the energy available in a 
simple fall on to the hip is 15 times greater than the energies required to fracture the 
elderly hip.31  One fourth of falls on the proximal femur result in hip fractures, 
whereas fewer than 2% of all falls cause this injury.  These studies suggest that a 
typical hip fracture is the result of a fall to the side and a subsequent impact on the 
greater trochanter of the proximal femur, where the energy-absorbing mechanisms 
of the host (e.g, outstretched hands to break the fall, reduced soft tissues at the site 
of impact) are inadequate to prevent fracture.75  
 
Hip Protectors 
 
 Over the past twenty years, many types of hip protectors have become 
available and are currently marketed around the world.  These protectors generally 
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fall into two distinct categories: those made with an energy-absorbing material and 
those that use a semi-rigid plastic shield to divert force from the trochanteric region 
to the soft tissue of the thigh.76  The hip protector that has been used in the majority 
of previous studies is the Safehip protector, made of stiff polypropylene on the 
outside and an inner lining of soft plastozote, and is designed to divert impact energy 
away from the greater trochanter.77   
The hip protector in the first Hip Impact Protection Project (HIP PRO) study, 
which provided data for our primary analyses, was made of a 0.32 cm outer layer of 
2.7-k g/m3 polyethylene vinyl acetate foam backed by a 0.95-cm layer of 0.9-kg/m3 
polyethylene vinyl acetate foam.16  The protectors, measuring 11.43 cm x 11.51 cm 
x 1.91 cm, were placed in the undergarments on only one hip and had previously 
been tested for bio-mechanical efficacy.78  The undergarments came in different 
types to accommodate the needs of individuals with dementia and incontinence, and 
were made of a Lycra/cotton material.   
 After termination of the first HIP PRO study, a second study of hip protectors 
was initiated using the FallGard FG-04 hip protector.  This hip protector was slightly 
more flexible than the hip protectors used in the first study and was composed of a 
dense (10 lbs / ft3), 0.57 inch layer of polyvinyl chloride (PVN) rubber foam, backed 
by a softer 4 lbs / ft3 PVN foam layer 0.18 inches thick.  The dimensions of this new 
hip protector were similar to the hip protectors used in the first study and used the 
same cotton Lycra undergarment. 
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Adherence to Wearing Hip Protectors 
 
 Older individuals are often unwilling to wear hip protectors, such that even 
initial acceptance of hip protectors is low.  The most important reasons for initial 
refusal include problems of fitting and discomfort, the perceived extra effort needed 
to wear the protectors (including difficulty wearing them when going to the 
bathroom), appearance, and the personal belief that they are not at risk for hip 
fractures.73, 79-81 The various studies that have measured initial acceptance of hip 
protectors (or initiation of use) have found that primary acceptance was low to 
moderate, ranging from 35% to 72%,41, 73, 77, 81-87 with initial acceptance higher 
among women (57%) than men.  Initial acceptance varied a great deal across 
studies but was highest in those randomized, controlled trials that devoted additional 
resources, such as nurses focused on improving adherence, and educational 
classes and materials about falls and hip fractures, to improve adherence.2, 88-93 
Studies in real-world settings, where, for example, hip protectors were mailed to 
community-dwelling residents, along with brochures on hip fractures and falls, 
showed the lowest level of initial acceptance. 
 Even among the highly selected group of individuals who initially find the idea 
of wearing hip protectors acceptable, adherence declined rapidly after initiation of 
most studies.  For example, in one study by Hubacher et al82, 38% of all initial 
wearers had stopped wearing the hip protectors by the end of the first month, by the 
end of the second month more than half had stopped (59%), and by the end of the 
third month more than two-thirds of initial wearers had stopped wearing the hip 
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protectors.  Although the declines were not as steep in other studies, adherence 
generally declined over time, with much of the decline occurring in the first few 
months of the study.87, 94-99  Comparison across studies is made difficult by the fact 
that adherence has been defined and measured in a variety of ways.  Some of the 
definitions included: average wearing time on active days and during waking hours, 
number of user-days per all available follow-up days, percentage of falls with hip 
protectors on, percentage of participants who were wearing the hip protector on 
most days, and percentage of participants who were wearing the hip protector at a 
certain moment.100  To complicate matters, the duration of follow-up varied 
significantly across studies.  Nevertheless, the impression persists of fairly low 
adherence by the end of the study period, in both observational and randomized 
studies.  In five of eight randomized controlled trials examining the effectiveness of 
external hip protectors, adherence with wearing hip protectors was lower or equal to 
50%.100  In some of the randomized studies, adherence rates were as low as 20%.89  
Many of the observational studies that have examined adherence have found 
adherence rates that were lower than 40% by the end of the study.7, 73-74, 82-83  
 The characteristics of institutional homes that impact long-term adherence 
include having health professionals dedicated to promoting adherence, the size of 
the institutional setting, and the type of institution (i.e., for-profit and not-for-profit).  
Having a dedicated health professional who promotes adherence with hip protectors 
increased adherence, when compared with institutional settings where no staff 
member was dedicated to improving adherence.   In one study by Parkkari et al101, 
the motivation of the institution staff, who were deeply concerned about the frequent 
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fall injuries among residents in the past, resulted in relatively high adherence rates.  
There were also differences in adherence, according to the type of person dedicated 
to promoting adherence.  In nursing homes where a nurse was the contact person 
for adherence, the probability of continued use was lower than when a physical 
therapist was the contact person.102  In general, larger nursing homes show a 
greater probability of continued use with the wearing of hip protectors than small 
homes.102  For-profit institutions have been noted to have lower long-term adherence 
than not-for-profit institutions.97, 99  The impact of other nursing home characteristics 
on adherence have not been vigorously examined.  However, anecdotal 
observations suggest that enthusiasm, workload, and other working conditions of the 
nursing staff may have a large influence on adherence.97  In a study by Cameron et 
al, relatively high long-term adherence of 76% during the day and 84% at night was 
noted in one home for the elderly.  This adherence was markedly different from other 
homes that were participating in the study, and was felt to have occurred mainly 
because of the enthusiasm and dedication of the nursing staff.76  
 The type of hip protectors, design, fit and appearance all play a role in the 
long-term adherence to the wearing of hip protectors.  Individual hip protectors, such 
as the Safehip protector, have been found to not be sufficiently comfortable to be 
worn at night by thin, severely disabled and cognitively impaired older women.103  
When comparing different types of hip protectors in two different studies, the 
comparison was between a soft hip protector and a hard hip protector.  Both studies 
noted that participants using the softer type were more compliant.84  In contrast, one 
study104 found no difference in the use of the Safehip design, which has a rigid, 
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concave shell that is designed to disperse the force of a fall away from the greater 
trochanter, when compared to the HipSaver design, which has a flexible foam 
protector that is designed to absorb the force of a fall.  While the Safehip garment 
was closer fitting and appeared less obvious under clothing, the HipSaver garment 
was looser and the protector was softer and more flexible, but was more easily 
visible under clothing.   Across numerous studies, poor fit was often identified as the 
reason for discontinuation.73, 81-82, 84, 97, 102, 105  For example, in one study, 70% of the 
drop-outs felt that wearing the protector was very uncomfortable.82  The problem of 
the tightness of the hip protectors cannot be completely resolved because hip 
protectors need to fit snugly over the greater trochanter to be effective.  However, 
improved design and the availability of additional sizes, could make hip protectors 
more comfortable and easier to remove,84 and could reduce the concerns about hip 
protectors being ‘too hot,’ ‘uncomfortable,’ and ‘irritating to the skin’.106  Appearance 
of the hip protectors was a concern to many residents,73, 81-82, 84 but especially 
women.105  More wearers who found the appearance of the hip protector as un-
attractive discontinued wearing the protectors.84  Conversely, a protective garment 
that did not show and looked well was associated with positive adherence. 81 
 Adherence to the wearing of hip protectors is influenced by a number of 
individual characteristics, including gender, age, cognitive status, history of falls and 
fractures, continence problems, self-efficacy, and physical status.  Individuals with 
mild or moderate urinary incontinence find the hip protector underwear acceptable, 
but difficulties are perceived for those residents who are severely incontinent.105   
Those individuals with urge incontinence report additional incontinent episodes 
 
 
21 
 
related to the use of the undergarments and require additional help with dressing 
and un-dressing.85   Both issues lead to increased staff support and often result in 
decreased adherence with the wearing of hip protectors.  Cognitive impairment 
results in increased agitation with the wearing of protective garments and, thus, 
decreased adherence for some individuals.10  Many individuals with cognitive 
impairment, however, once they acquire the habit of wearing the hip protector, wear 
it more habitually.91, 104, 107  The probability of wearing hip protectors also increases 
for individuals with an increasing number of fall risk factors (two fall risk factors: 
OR=1.47 (0.83, 2.60); three or more risk factors: OR=2.02 (1.10, 3.71).82  Individuals 
who have a history of actually falling also are more likely to be adherent with the 
wearing of hip protector undergarments.10, 84, 86-87  A history of fractures or other 
significant injury in the past twelve months, subsequent to a fall, was predictive of 
higher adherence.81, 104  Being female was associated with increased adherence, 
possibly because women are more susceptible to adherence encouragement by 
staff, who are also largely female81-82, 102;increasing age, in contrast, resulted in 
lower adherence.84  Finally, individuals with a lower perceived self-efficacy for hip 
protector use and lower self-rated health were more likely to be adherent with the 
wearing of protective undergarments.108 These individuals are more physically 
dependent and are more susceptible to the influence of staff who encourage them to 
wear protectors.84, 104  Individuals with physical and mental deficiencies are relatively 
powerless, especially in institutional settings, where their satisfaction depends 
largely on staff.104  In institutional settings with a high percentage of individuals with 
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dementia and/or physical disabilities, adherence is significantly impacted by the 
commitment of nursing and personal care staff in the institution.76  
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HIP PROTECTOR EFFECTIVENESSS 
 
Search Strategy and Inclusion Criteria 
 
 A literature search of all hip protector studies was conducted using the 
PubMed, CINAHL, Cochrane, ISI Web of Science, and EMBASE databases on 
November 13, 2006, and was repeated on August 5, 2009.  The specific search 
criteria for each of the databases are identified in Appendix I.  Briefly, the search 
was limited to randomized control trials (RCTs) in humans, found in full publications, 
abstracts, and non-English language articles, in which the intervention was a hip 
protector of any type, and the outcome was a primary or secondary hip fracture.  
This initial review of the literature resulted in the identification of 48 articles from 
PubMed, 30 from CINAHL, 43 from Cochrance, 11 from ISI Web of Science; from 
EMBASE we restricted the search to articles not already identified from PubMed and 
found 4 additional publications.   
 In addition, we reviewed all references of any selected articles from the 
database search, as well as all references in the systematic review of hip protectors 
by Waldegger et al7, Sawka et al79, and Parker et al109.  When reviewing the titles of 
articles found in the reference section of previously identified articles and systematic 
reviews, we retained for further review only articles that had in the title at least one 
item from each of the two sub-headings below: 
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 Heading 1     Heading 2 
 Effectiveness    Fall  
 Intervention     Fracture 
 Trial      Hip  
 Randomized     Hip Protector 
 Prevent     Hip Pad 
 Harmful   
 
Other titles could be selected only if highly suggestive of a study of hip protectors to 
prevent hip fractures. 
 A total of 697 articles were initially identified by conducting the database 
search and title search.  Of the total 697 articles initially identified for review, 43 
articles which met the inclusion criteria for the database search and 7 articles which 
had in the title at least one item from each of the two sub-headings above were 
selected for a full abstract review.  Abstract review revealed 16 randomized studies 
of hip protectors in which the outcome was a hip fracture.  These studies are 
described in greater detail in Appendix 2, with particular emphasis on demonstrated 
efficacy and adherence. 
 
Summary 
 
 Of the sixteen studies included in these analyses, ten were carried out in 
Europe, two in Australia, two in Japan, and two in the United States (Table 1.1).  
Most of the studies were presented as full manuscripts; however, data for five 
studies were available only in abstracts, short reports, or letters to the editor.  The 
majority of hip protector studies after 2000 used a protector whose bio-mechanical 
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properties had been clearly documented, the Safehip protector.  For the remaining 
studies, the type of hip protector was either specifically designed for the randomized 
study or used an alternate commercially available hip protector such as the KPH hip 
protector or the JOFA AF hip protector.  Many of these alternate hip protectors also 
provided evidence of bio-mechanical effectiveness, with the notable exception of the 
Ekman and Villar studies.87, 110  There was variability in the design of hip protectors.  
The Safehip protector had an outer shield of polypropylene with an inner plastozote 
lining, sewn into a special cotton-lycra underwear.  The two hip protectors used in 
the HIP PRO studies have been described previously and shown to be different from 
the Safehip protector.  The protector used in the Ekman110 study used closed-cell 
polyethylene foam, which was similar to the material used in knee protectors of 
hockey players.  In contrast, the Villar87 protector was made of polypropylene which 
was encased in compressed polystyrene.  The remaining non-Safehip protectors 
were not described in greater detail.  A total of 12 studies occurred in long-term care 
settings, while the remaining four studies were carried out in community settings.  Of 
the studies undertaken in long-term care settings, all studies were cluster 
randomized except for the Cameron 2001103 and van Schoor studies.107 
 Not all studies provided information on the demographic characteristics of the 
study population, particularly those randomized studies which presented results in 
abstracts, short reports, or letters to the editor.  The median or mean age of study 
participants ranged from 78 to 86 years, indicating that most study participants were 
elderly (Table 1.2).  The study inclusion/exclusion criteria of five studies limited the 
study population to females.  The remaining studies with non-missing gender 
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suggested that the majority of participants were female, reflecting the fact that 
women tend to survive longer than men.  We will contact the authors of the studies 
with missing information on gender and age to completely describe the study 
population of included studies.  The total follow-up time ranged from 3 months in the 
Villar87 et al study to 28 months in the Birks et al study. 
 Adherence ranged from a low of 20% in the O’Halloran et al83 study to a high 
of 88% in the Koike et al study111 (Table 1.3).  The adherence in the Koike study is 
surprisingly high, relative to most of the other studies.  This high level of adherence 
may have been the result of cultural differences.  The adherence of the Koike et al111 
and the Harada et al91 study (70%) were both at the high end of the range and both 
occurred in Japan.  The way that adherence was defined was unique in almost all of 
the studies, making comparison across studies difficult.  In five studies, adherence 
was not defined or not clearly explained.  Four studies defined an adherent 
participant as one who wore the hip protector daily during waking hours.  For the 
remainder of the studies, adherence was defined on a continuum, ranging from such 
definitions as ‘wears protectors for a minimum of one hour per day’ or wears 
protectors ‘most of the time’ to more strict definitions noting that a participant was 
adherent only if they wore the protector 24 hours a day.  Despite the variability in 
how adherence was defined, there did not appear to be a relationship with overall 
adherence.  We would expect that more lenient definitions of adherence would result 
in higher overall percent adherence – however, this was not always true.  
 Other factors that may have influenced overall adherence included such items 
as who checked adherence, the frequency of the adherence checks, and whether 
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the adherence check occurred at random times.  There were three studies in which 
adherence was assessed by self-report, three studies in which it was evaluated by 
caregivers, five studies in which adherence was reported by research staff, and 
three studies where this information was not provided.  Based on previous studies of 
adherence, one would expect that individuals providing self-reports and caregivers 
may have inflated adherence, while the adherence reported by research staff may 
have been the most objective and least prone to error.  However, no clear 
relationship was evident in the included studies between overall adherence and who 
checks the adherence.  Note that only in four out of five studies where adherence 
was evaluated by research staff had random adherence checks.  For a few studies 
adherence was checked daily or three times a week; for the remainder of the studies 
adherence was infrequent, with the Birks 2004112 study having the greatest time 
between adherence checks, evaluating adherence every six months. 
 Only a few of the studies met the majority of criteria that denote a high quality 
randomized study in which the eligibility criteria are clearly described, baseline 
demographic characteristics are tabulated, it is clear that those evaluating the 
outcome were blinded to the exposure, the attrition from the study is described, the 
study achieved the proposed sample size, and an ITT analysis was undertaken 
(Table 1.4). In particular, the earliest two studies of hip protectors (which showed a 
strong protective effect of hip protectors) were of poor quality (Lauritzen88 and 
Ekman110). But even the two highest quality studies of Kannus et al89 and Kiel et al16 
either failed to indicate whether the outcome assessor was blinded or failed to 
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accrue sufficient study participants because of an over-optimistic assumption of hip 
fracture rates. 
 In evaluating efficacy, we excluded from the analysis two studies in which the 
hip protector protected only one hip (Birge113, Kiel16) and one study in which the 
outcome was a second hip fracture (Birks 2004).112  The mechanism of biologic 
action was perceived to be different in these three studies because of differences in 
design or because the study population was at a much higher risk of hip fracture.  
This left 13 studies for the evaluation of efficacy (Figures 1.2-1.5). For one study in 
which there were no events in the protected and unprotected hips (Villar),87 we used 
the simple continuity correction of Sweeting et al114, so that this study could be 
included in the analysis.  We add 0.5 to each of the four cells in the 2 X 2 table.  
With this method, the data equivalent prior for the analysis of the Villar study87 
(which received the continuity correction) was based on a hypothetical previous 
study with N=2, a balanced design (N1=N0=1), and OR=1.0.   
 For the included studies, we evaluated publication bias by evaluating funnel 
plot asymmetry with the trim and fill method of Duval and Tweedie.115  Funnel plot 
asymmetry was not indicated by visual inspection, and the trim and fill method did 
not impute data for any hypothetically missing studies.   This suggested that there 
was no publication bias for the included hip protector studies. 
 Heterogeneity between studies was examined by calculating a p-value for the 
Cochran Q, which was defined as 
13
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= 12) degrees of freedom.  Pronounced heterogeneity was observed in the 13 
included hip fracture studies (Cochran Q=41.09, p<0.0001).  This heterogeneity is 
explored in Figures 1.2-1.5, which present forest plots of the risk difference and 95% 
confidence intervals of each of the individual studies, as well as a random effects 
summary risk difference and its associated 95% confidence interval.  Each figure 
presents the studies in order, by four study characteristics that are hypothesized to 
cause the observed between-study heterogeneity.  Figure 1.2 presents the studies in 
order of total follow-up time.  Shorter duration studies, those with follow-up of 
months or less, appear to show a stronger protective effect of hip protectors, but this 
relationship does not appear strong.  In figure 1.3 we present data for included 
studies, by overall adherence.  We would expect that studies with lower adherence 
would be more likely to be biased toward the null.  However, this does not appear to 
be the case, possibly because of the great variability in how adherence is defined 
and measured.  The three studies in Figure 1.4 which were in community settings 
appear to be different from the studies that occurred in long-term care settings.  
Importantly, we excluded one study by Birks et al112 which was in the community and 
revealed a precise risk difference of 0.04.  This study was excluded because the 
outcome that was evaluated was a second hip fracture.  Finally, figure 1.5 orders the 
included studies by whether the intervention was a Safehip protector or some other 
protector.  The non-Safehip protector studies appear to have a somewhat stronger 
protective effect, when compared to the studies of Safehip protectors.  While some 
of these study characteristics seem to explain some of the heterogeneity in the 
included studies by visual inspection, a more thorough analysis requires the use of 
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meta-regression.  We have chosen to defer a meta-regression until we are able, if 
possible, to fill in missing information on gender and age for some of the included 
studies. 
 
Discussion 
 
 The earliest studies to investigate the protective effect of hip protectors were 
founded on extensive biomechanical testing of the hip protectors, as well as on 
mounting evidence that hip fractures occurred mainly as a result of a fall on to the 
greater trochanter, where the skin and subcutaneous fat were insufficient to absorb 
and disperse the force of the fall, and the underlying bone had deteriorated as a 
result of osteoporosis.  Lauritzen et al88 randomized nursing homes in a 1:2 ratio to 
either receive hip protectors or not receive hip protectors; 215 individuals received 
hip protectors, and 418 did not.  The relative risk for hip fracture was 0.44 
(0.21,0.94), when comparing the intervention hip–protector group to the controls.88  
Other, smaller randomized studies in the late nineties also hinted at a strong 
protective effect of hip protector.87, 110, 116  The design and analysis of these early 
studies, however, was questioned, bringing into doubt the findings from these early 
studies.  In the Lauritzen et al88 study, for example, individuals who died were 
replaced by new arrivals from a waiting list, leading to the possibility of selection bias 
(i.e., individuals might have gained admission preferentially to a nursing home that 
was randomized to wearing hip protectors).  Also, in the Lauritzen study, 
randomization occurred at the nursing home level, but analysis was conducted at the 
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individual level.  The main consequence of adopting a cluster design is that the 
outcome for each patient can no longer be assumed to be independent of that for 
any other patient.  Patients within any one cluster are more likely to have similar 
outcomes.117  If the clustering effect is ignored, confidence intervals might be over-
narrow, increasing the chances of spuriously significant findings and misleading 
conclusions.117  
 Additional studies of hip protectors, some of which attempted to address the 
design flaws and analysis flaws of earlier studies, were conducted in the first part of 
the new millennium, in both institutional settings and in the community.83, 89, 91, 94-96, 
103, 112, 118 Systematic reviews of the efficacy of hip protectors included different 
studies, according to the strictness of their inclusion/exclusion criteria, and came to 
conflicting conclusions.7, 79, 109  The systematic review by Waldegger et al included 
only five studies which were conducted in institutional settings.88-89, 91, 110, 119  Their 
results indicated a relative risk of hip fractures of 0.35 (0.23, 0.51), when comparing 
the hip protector intervention group against controls and noted no significant 
heterogeneity between studies. 7 Another analysis by the Cochrane group109, 
included many more studies that were carried out in nursing or residential care 
settings, as well as a few studies that were conducted in the community.82-83, 88-89, 91-
92, 94-96, 110, 112, 116, 118-119  They noted that hip protectors are an ineffective intervention 
for those living at home (RR=1.16 (0.85, 1.59)), but are marginally protective in 
individuals living in institutions who have access to care staff that encourage 
adherence and provide help with the protective undergarments (RR=0.77 (0.62, 
0.97)).  Sawka et al, in their systematic review, used much stricter 
 
 
32 
 
inclusion/exclusion criteria and excluded cluster randomized trials that did not 
account for the clustering in the analysis, as well as trials that allowed individuals 
who died or were lost to follow-up to be replaced by other individuals from a waiting 
list.  In the four trials that were included in their analysis95-97, 112, they found no 
protective effect of hip protectors (RR=1.07 (0.81, 1.42)).79  These results from the 
systematic reviews of protective undergarments, as well as the results from the 
individual studies, provide conflicting evidence of the effectiveness of hip protectors 
to prevent hip fractures. 
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Table 1.1 Characteristics of 16 Studies of the Risk of Hip Fractures Among Elderly Individuals 
Wearing Hip Protectors When Compared with Individuals not Wearing Hip Protectors. 
First 
Author 
 
Year 
 
Country 
Publication 
Type 
SafeHip 
Protector 
Long-term 
Care Setting 
Cluster 
Randomization 
Lauritzen 1993 Denmark Manuscript No Yes Yes 
Ekman 1997 Sweden Short Report No Yes Yes 
Jantti 1998 Finland Letter No Yes No 
Villar  1998 U.K. Manuscript No No No 
Kannus 2000 Finland Manuscript No Yes Yes 
Birge 2001 U.S. Abstract No Yes Yes 
Cameron 2001 Australia Manuscript Yes Yes No 
Harada 2001 Japan Manuscript No Yes Yes 
Birks 2003 U.K. Short Report Yes No No 
Cameron 2003 Australia Manuscript Yes No No 
Meyer 2003 Germany Manuscript Yes Yes Yes 
van Schoor 2003 Netherlands Manuscript Yes Yes No 
Birks 2004 U.K. Manuscript Yes No No 
O’Halloran 2004 Ireland Manuscript Yes Yes Yes 
Koike 2005 Japan Abstract Yes Yes Yes 
Kiel 2006 U.S. Manuscript No Yes Yes 
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Table 1.2.  Summary Patient Characteristics of 16 Studies Evaluating the Risk of Hip Fractures 
 
First Author 
 
Year 
Total Follow-up 
(Months) 
Mean or Median 
Age 
 
% Female 
Lauritzen 1993 11 . 67 
Ekman 1997 11 84.0 . 
Jantti 1998 12 . . 
Villar  1998 3 81.4 100 
Kannus 2000 24 82.0 78 
Birge 2001 12 . . 
Cameron 2001 18 85.0 100 
Harada 2001 12 83.2 100 
Birks 2003 14 80.5 87 
Cameron 2003 24 83.0 100 
Meyer 2003 18 86.0 86 
van Schoor 2003 17 85.0 89 
Birks 2004 28 77.8 100 
O’Halloran 2004 18 . . 
Koike 2005 10 . 100 
Kiel 2006 20 85.3 79 
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Table 1.3. Adherence Characteristics of 16 Studies Evaluating the Risk of Hip Fractures. 
 
First 
Author 
 
 
Year 
 
% 
Adherence 
 
Adherence 
Definitiona 
 
Who Checks 
Adherence? 
Frequency of 
Adherence 
Checks 
Random 
Adherence 
Checks? 
Lauritzen 1993 24.0 . . . . 
Ekman 1997 44.0 . . . . 
Jantti 1998 44.0 . . . . 
Villar  1998 26.7 9 Research Staff Fortnightly Yes 
Kannus 2000 48.0 8 Caregiver Daily No 
Birge 2001 63.0 7 . . . 
Cameron 2001 57.0 1 Research Staff Day 18, 67, 
321, 544 
No 
Harada 2001 70.0 5 Caregiver Daily No 
Birks 2003 22.0 1 Self-report . No 
Cameron 2003 53.0 1 Self-report Month 1, 3, 
12, 18, 24 
No 
Meyer 2003 67.0 3 Caregiver . No 
van Schoor 2003 37.0 9 Research Staff Month 1, 6 12 Yes 
Birks 2004 31.0 2 Self-report Every 6 
Months 
No 
O’Halloran 2004 19.9 6 Research Staff Weeks 2, 4, 8, 
12, 18 
No 
Koike 2005 87.5 1 . . . 
Kiel 2006 77.8 4 Research Staff 3 X Week Yes 
 
aParticipant was deemed to be adherent according to different definitions: (1) wears daily during 
waking hours, (2) if wears the protector ‘most of the time’, (3) when wearing protector during a fall, (4) 
wearing protector at time of adherence visit , (5) wears protectors 24 hours a day, (6) wearing 
protector at time of nurse facilitator visit, (7), during time out of bed, (8) wearing protector for minimum 
of one hour per day,  (9) not clear 
 
 
 
36 
 
Table 1.4.  Quality of 16 Studies Evaluating the Risk of Hip Fractures. 
 
First  
Author 
 
 
Year 
Eligibility 
Criteria 
Described? 
Outcome 
Assessors 
Blinded? 
 
Attrition 
Described? 
 
ITT 
Analysis? 
Achieved 
Sample 
Size? 
Baseline 
Variables 
Tabulated? 
Lauritzen 1993 No . No Yes . No 
Ekman 1997 No . No Yes . Yes 
Jantti 1998 Yes . Yes Yes . No 
Villar  1998 Yes . Yes . . No 
Kannus 2000 Yes . Yes Yes Yes Yes 
Birge 2001 Yes . No Yes . No 
Cameron 2001 Yes No Yes Yes No Yes 
Harada 2001 Yes . No Yes . Yes 
Birks 2003 Yes No Yes Yes No Yes 
Cameron 2003 Yes Yes Yes Yes No Yes 
Meyer 2003 Yes . Yes Yes Yes Yes 
van Schoor 2003 Yes No Yes Yes No Yes 
Birks 2004 Yes No Yes Yes No Yes 
O’Halloran 2004 Yes . Yes Yes Yes Yes 
Koike 2005 Yes . Yes Yes . No 
Kiel 2006 Yes Yes Yes Yes No Yes 
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Figure 1.2. Summary Risk Differences and 95% Confidence Intervals for the 
Effect of Hip Protectors, by Follow-up 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 71.2%, p = 0.000)
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 Figure 1.3. Summary Risk Differences and 95% Confidence Intervals for the 
Effect of Hip Protectors, by Adherence 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 71.2%, p = 0.000)
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Figure 4. Summary Risk Differences and 95% Confidence Intervals for the 
Effect of Hip Protectors, by Setting 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 71.2%, p = 0.000)
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Figure 5. Summary Risk Differences and 95% Confidence Intervals for the 
Effect of Hip Protectors, by Hip Protector Type (SafeHip vs Other) 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 71.2%, p = 0.000)
Ekman
vanSchoor
Harada
Kannus
Study
Birks
Jantti
ID
Cameron2
OHalloran
Meyer
Villar
Cameron
Lauritzen
Koike
-0.02 (-0.04, -0.01)
-0.03 (-0.05, -0.00)
-0.00 (-0.04, 0.04)
-0.09 (-0.17, -0.02)
-0.04 (-0.06, -0.02)
0.00 (-0.01, 0.01)
-0.17 (-0.31, -0.03)
ES (95% CI)
-0.00 (-0.05, 0.04)
0.00 (-0.01, 0.02)
-0.04 (-0.07, -0.00)
-0.01 (-0.04, 0.03)
0.01 (-0.07, 0.10)
-0.04 (-0.08, -0.01)
-0.04 (-0.07, -0.01)
100.00
10.54
6.64
3.16
11.63
%
12.97
1.02
Weight
6.60
11.99
8.58
7.51
2.52
8.05
8.78
0
1
0
0
1
0
safehip
1
1
1
0
1
0
1
  
0-.307 .307
 
 
CHAPTER 2 
 
METHODS 
 
To date, a number of studies have been conducted into the efficacy of hip 
protectors to prevent hip fractures: the results have been mixed.82-83, 88-89, 91, 94-96, 103, 
110, 112, 116, 118-119 Notably, in all of these studies, those that demonstrated the efficacy 
of hip protectors and those that did not, adherence to the wearing of protective 
undergarments has been low.  No study has noted an adherence rate above 80%, 
and most have overall adherence rates that are below 50%.  This is true in 
observational studies, as well as in randomized controlled trials.  Despite adherence 
rates that are below 80%, sometimes substantially below 80%, the randomized 
studies report intention-to-treat (ITT) results as if they were causal effect estimates.  
Such low adherence rates, however, eliminate the benefits of randomization as a 
tool to estimate etiologic effects and may result in biased effect estimates.  We 
propose to correct for the poor adherence in on one randomized trial with three 
relatively new methods for compliance correction, instrumental variable analysis120-
121, inverse probability of censoring weights (IPCWs)122, and structural nested 
models (SNMs).123-124 
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STUDY SETTING AND CLINICAL PROCEDURES 
 
 For these analyses, we will use data from the Hip Impact Protection Project 
(HIP PRO), a multi-center, randomized, controlled trial of the efficacy of an energy 
absorbing hip protector for the prevention of hip fractures in nursing homes.16, 125  
This study was conducted in three states, Massachusetts, Maryland, and Missouri, 
with data collection beginning in October 2002 and continuing through August 2006.  
HIP PRO was designed to eliminate some of the design flaws of previous studies.  
Hip protectors were designed to be worn on only one hip, so that only one hip would 
be protected, and each individual would serve as his/her own control.  
Randomization of the side of the hip to be protected occurred at the level of the 
nursing home.  As in other studies, significant efforts were expended to improve 
adherence.  Unlike previous studies, adherence was assessed three times a week at 
randomly timed visits by study staff.  The hip fracture outcome was evaluated by at 
least two members of a Clinical Endpoints Committee; all members of the Clinical 
Endpoints Committee were blinded to the side of the protected hip. 
 HIP PRO was a study designed to investigate the efficacy and safety of hip 
pants in the prevention of hip fractures in an elderly nursing home (NH) population.16  
With a unique under-garment design, it attempted to address some of the problems 
of earlier hip protector studies in NHs.  Residents wear a hip protector (of the energy 
absorbing and shunting type) on one hip, so that each resident serves as his or her 
own control.  This design feature eliminates the problems of selection bias that were 
present in previous studies.  Randomization as to the side that the hip protector 
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would be worn on was done at the nursing home level, mainly for logistics and 
convenience.  The main research aims of the HIP PRO study were to: (1) determine 
whether a trochanteric pad, inserted into undergarments with a pocket on one side, 
will reduce the incidence of hip fracture on the protected side by 50%, when 
compared to unprotected side, in elderly NH residents; (2) evaluate those resident-
level and facility-level factors that impact adherence with the wearing of the 
protective undergarments. 
 To address these aims, intermediate and skilled nursing facilities that had a 
minimum of 100 beds, had participated in other research projects, employed charge 
nurses who are not from agencies, had a good reputation among health care 
providers and families, and were geographically close to a HIP PRO Clinical Center 
were recruited into the study.  These screening criteria were designed to screen out 
those facilities that might provide poor quality data or who might drop out early from 
the study.  Within each enrolled facility, a complete census of residents was taken 
and residents who were older than age 65, had gotten out of a bed or chair without 
human assistance in the past 4 weeks, and were in a non-Medicare, non-acute, non-
rehabilitation bed, were identified as potential candidates for inclusion in the study.  
Residents with any of the following criteria were excluded from the HIP PRO study: 
(1) refused consent or a responsible party refused to give informed consent, (2) had 
a hip circumference greater than 48 inches, (3) had pressure sores, skin tears, or 
skin shearing in readily viewable areas over bony prominences covered by the hip 
protector undergarment, (4) had prior bilateral hip fractures or hip replacement, (5) 
had bilateral surgical scars over both hips, (6) had a terminal illness expected to 
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result in death in the next 6 months, (7) had signs or symptoms of a hip fracture at 
the time of enrollment, (8) refused to have their hips examined at the time of 
enrollment, (9) generally refused to wear clothing during the day, (10) were in 
isolation for a contagious disease, or (11) the nursing home staff strongly 
recommended not approaching. 
   
Hip Fracture Outcome 
 
 The majority of hip fractures require surgery to stabilize the fracture, reduce 
the pain associated with the hip fracture, and allow the healing process to begin.  
Consequently, most of the hip fractures in HIP PRO were evident and readily 
identified.  However, to make sure that HIP PRO identified all hip fracture outcomes, 
a fracture surveillance protocol was initiated.  The purpose of the surveillance 
program was not only to identify all fractures, but also to ascertain whether the 
protective underwear and protector were being worn at the time of the fall and the 
protector was properly positioned.  The main source of hip fracture identification in 
the fracture surveillance program was the fracture reporting hot line.  Nursing home 
staff who became aware of a hip fracture were expected to call the fracture reporting 
hot line.  Once the hot line had been activated the following items were completed: 
(1) a Fall Report Form, and (2) a Resident Hospitalization Form.  When a hip 
fracture was not reported to the study hotline and the study staff became aware of 
the hip fracture during site visits, the research assistant was expected to complete 
the relevant forms.  Also, any transfer of a participating member to a hospital 
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resulted in a request for all hospitalization records, so that it could be determined 
whether a hip-fracture did or did not occur.  At times, hip fractures occurred that did 
not require hospitalization and were not apparent to nursing home staff.  Study staff 
were trained to also check for signs and symptoms of clinically unapparent hip 
fractures in participating residents.  These signs and symptoms included: (1) new 
pain in the hip region that was not present at previous visit, (2) new and acute 
inability to bear weight or transfer, (3) acute change in mobility not due to other 
obvious reason, (4) externally (occasionally internally) rotated leg, and (5) bruise or 
skin tears over the femoral trochanter.  Any hip fractures that were suspected but 
clinically unapparent were confirmed by radiologic examination. 
 All hip fractures were evaluated by at least one orthopedic surgeon and one 
geriatrician, using information from ER visits, hospital discharge summaries, x-ray 
reports, and operating notes.  If these two physicians were not able to agree about 
the hip fracture outcome, a second orthopedic surgeon was contacted to act as the 
tie-breaker.  Particularly difficult cases were discussed and a consensus for these 
cases was reached at annual meetings by the full five-member HIP PRO Clinical 
Endpoints Committee (CEC). 
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Adherence 
 
Two-Week Run-In Period 
 
 After the resident was deemed eligible for the study and had signed informed 
consent, he/she went through a two-week adherence run-in period.  During this two 
week run-in period, HIP PRO staff made three unannounced visits per week to the 
nursing home.  If the resident demonstrated adequate adherence (undergarment on 
forward with the waistband in the proper position, protector in proper placement over 
the greater trochanter) during the run-in period in four out of the six total visits, that 
resident could then continue to participate in the main HIP PRO study.  All six 
adherence checks in the two week run-in period were required for subsequent data 
analysis. 
 
Main Study 
 
 One of the unique features of HIP PRO and one of its main strengths was the 
monitoring of adherence by study staff.  Study staff monitored adherence during 
three random, unannounced visits per week.  These visits occurred at any time 
during the week, including weekends and all shifts, with the exception that residents 
were not disturbed between the hours of 10 p.m. and 6 a.m.  Although fractures do 
occur at night, the vast majority occur during waking hours and the adherence visits 
were designed to occur during the hours when residents were most at risk for hip 
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fractures.  During the adherence visits, the staff noted the date, time, and results of 
the visit, including, if the resident was non-adherent, the reason for the non-
adherence.  When a hip fracture was suspected and the resident was not available 
in the nursing home, adherence was reported by the resident or responsible family 
member.  These adherence reports were marked as self-reports and were obtained 
from the resident if she had a Short Blessed Test (SBT)126 score less than 12 or 
from the family member if the resident had an SBT score greater than 12.  Residents 
not contributing any adherence data for more than five weeks (due to hospitalization, 
transferred to another institutional setting, etc.) were withdrawn from HIP PRO.  The 
adherence monitoring data for any particular HIP PRO staff were compared to the 
adherence monitoring data of a second observer who independently assessed 
adherence.  These checks on the quality of the adherence data were done at the 
beginning of the study and every six months thereafter.  Nursing homes that 
demonstrated poor overall adherence for a period of two months or more were 
provided with additional training.  Continued poor adherence resulted in recruitment 
being stopped at that nursing home.  
 
Factors Affecting Adherence 
 
 There are many individual-level and facility-level variables that could 
potentially impact adherence with the wearing of protective under-garments.  The 
individual-level characteristics include demographics (age, educations status, 
gender, etc.), past fall/fracture history, other medical history, assessment of physical 
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functioning, level of agitation, etc.  All of these factors were assessed at the baseline 
visit.  For those residents who are not cognitively impaired (i.e., have a Short 
Blessed Test score less than 12), additional information about fear of falling, body 
image rating, and perceived need for hip protectors was assessed because these 
factors have been shown to impact adherence in other studies.  Facility-level factors 
that could potentially impact adherence, including facility size, ownership, affiliation, 
staff turnover, number of temporary staff, and others, were collected during baseline 
interviews with the director of nursing and the nursing home administrator. 
 
Study Results – HIP PRO Study I 
 
 HIP PRO started enrolling nursing homes and residents in October 2002.  
The hip protector that was initially used in HIP PRO was made of several different 
materials, including polyethylene and ethylene vinyl acetate.  The hip protector, with 
dimensions of 4.5” x 6.5” x 0.79” was placed in an undergarment, which was 
produced and distributed by FallGard Co. of Napaville, Illinois, of high-quality cotton 
Lycra.  After 20 months of follow-up, the first study was terminated due to lack of 
efficacy.  In this first study there were a total of 1042 residents who were deemed 
eligible for the study.  Of these, 192 did not complete the two-week adherence run-in 
period; however, all individuals were included in the final analysis.  The study 
population was characterized as being primarily female (79%), of white ethnicity 
(86%), were severely cognitively impaired (71%) and had a mean age of 85 years 
(s.d. 7.4).  Residents exhibited a range of physical functioning, and were, for the 
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most part, at least partially incontinent of bladder and bowel.  There were a total of 
69 (7%) individuals with a history of hip replacement, 163 (16%) with a history of hip 
fractures, and 301 (29%) with a history of falls in the past 30 days.  The nursing 
homes which contributed data to this study were large (>100 beds) and equally likely 
to be for-profit and not-for-profit. 
 Each resident could contribute only one hip fracture and was removed from 
the study after the index hip fracture.  As a result, we do not worry about correlation 
within individuals, despite the fact that the same individual contributed a protected 
and unprotected hip.  Clustering within nursing homes was ignored for the main 
analysis since the intra-class correlation (ICC) was small.  After 676 hip-years of 
follow-up, 21 hip fractures occurred in protected hips and 17 hip fractures occurred 
in unprotected hips.  Out of a total of 1042 enrolled NH residents, 38 (4%) 
experienced the primary outcome (Table 2.1).  The first HIP PRO study was 
terminated early due to a lack of efficacy.  The intent-to treat analysis found a 
matched rate ratio of 1.24 (95% confidence interval of 0.65 to 2.34), when 
comparing hips which were randomly assigned to be protected with the contra-
lateral hips which were not protected.    
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Table 2.1.Hip Fractures on Protected versus Unprotected Hips (HIP PRO1 Study 1) 
 Intent-to-Treat (N=1,042) 
 Protected Unprotected 
Number of Hip Fractures 21 17 
Hip-Years of Observation 676 676 
Incidence Rate 3.1 (1.8, 4.4) 2.5 (1.3, 3.7) 
1Hip Impact Protection Project. 
 
Adjusting for clustering within nursing homes did not meaningfully change the 
results.  Kiel et. al.16 also noted that in residents who had an overall adherence of 
80% or greater (32% of all residents), 15 hip fractures occurred in protected hips and 
10 hip fractures occurred in unprotected hips, across a total of 284 hip-years of 
observation.  If we assume in this subset of ‘adherent’ residents, as was true for the 
total study population, that protected and unprotected hips had equivalent follow-up, 
that no individual had more than one hip fracture, and that the intra-class correlation 
between nursing homes is small, the matched per-protocol rate ratio, comparing hip 
fractures in protected and unprotected hips, would be 1.50 (0.67, 3.34). 
The overall adherence for all residents, who were followed up over an 
average of 7.8 months, was 73.8%.  At the beginning of the study adherence was 
initially 60%, but increased to approximately 80% at the 6-month point, before 
starting to decline down to approximately 70% by the end of the study.  
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Study Results – HIP PRO Study II 
 
After the first HIP PRO study was terminated, a second study, using similar 
methods, but incorporating a different hip protector, was conducted.  The hip 
protector used in the second study was the FallGard FG-04 hip protector.  In the 
second study, a total of 1445 residents contributed 1004 hip years of observation 
between October 2004 and August 2006.  Some nursing home residents were 
switched to the new hip protector after termination of the first study, while 988 
entirely new residents were also enrolled into the second hip protector study.  As in 
the first study, participating residents had a mean age of 85 ± 8 years, and were 
primarily women (78%), white (86%), and had severe cognitive impairment (72%).  
All but four nursing homes participating in the first study also contributed data to the 
second study; in addition, 18 new nursing homes were recruited.  These nursing 
homes were large (≥ 100 beds), mainly not-for-profit institutions (55%). 
 In the second HIP PRO study, after 1004 hip-years of follow-up, 17 hip 
fractures occurred in protected hips and 15 hip fractures occurred in unprotected 
hips (Table 2.2).  The intent-to-treat analysis in this second study found a matched 
rate ratio of 1.13 (95% confidence interval of 0.57, 2.27), when comparing protected 
hips to unprotected hips.  Again, adjusting for clustering within nursing homes did 
not meaningfully change the results. 
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Table 2.2.Hip Fractures on Protected versus Unprotected Hips (HIP PRO1 Study 2) 
 Intent-to-Treat (N=1,445) 
 Protected Unprotected 
Number of Hip Fractures 17 15 
Hip-Years of Observation 1004 1004 
Incidence Rate 1.7 (1.1, 2.7) 1.5 (0.9, 2.5) 
1Hip Impact Protection Project. 
 
Causal Inference and the HIP PRO Study. 
 
As has been long established, causal effect estimates can be consistently 
estimated in randomized experiments under certain ideal situations.  Assuming a 
sufficient sample size, no loss to follow-up, and full adherence with treatment, the 
observed conditional risk (Pr[Y=1|A=a]) in a randomized study is equal to the 
marginal counterfactual risk (Pr[Ya=1]); therefore, the associational risk ratio (or risk 
difference or odds ratio) from a randomized study is equal to the causal risk ratio (or 
risk difference or odds ratio).127  In essence, the two groups produced by 
randomization are comparable or, more precisely, exchangeable.  As a result, which 
particular group receives the treatment is irrelevant.  This simple consequence of 
randomized studies means that under ideal conditions, the associational effect 
estimates obtained from randomized studies are causal effect estimates. It should 
be mentioned that, among other things, an ideal experiment would also have no 
measurement error of the exposure and outcome, and there would be no biases 
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arising from the fact that the participant, the healthcare workers responsible for the 
participant’s treatment, or the person responsible for measuring or evaluating the 
outcome know which treatment has been allocated. Such an ideal experiment may 
not be feasible in a real world setting; however, it provides a conceptual framework 
in which determination of a ‘causal’ relationship would be feasible.128   
Unfortunately, as we move away from an ideal randomized study, the effect 
estimates obtained from randomized studies can no longer be viewed as causal 
effect estimates.  Specifically, in the presence of non-adherence, an intention-to-
treat (ITT) analysis guarantees only exchangeability of two groups that are now 
defined by a misclassified exposure (the original treatment assignment).  It has 
sometimes been suggested, incorrectly, that the as-treated analysis or the per-
protocol analysis resolves this problem.  While these analyses do guarantee a 
correct classification of exposure, they do not guarantee exchangeability of the 
groups defined by this exposure.  The advantage of the ITT analysis, when 
compared to the as-treated analysis and the per-protocol analysis, is that it provides 
an unbiased associational measure (and, thus, a causal effect estimate) if the casual 
null hypothesis holds for the exposure that was actually observed under non-
adherence.  (As an aside, note that in randomized trials with a survival endpoint the 
treatment effect can be evaluated with the following proportional hazards model: λi(t) 
= λ0(t) exp(ψHRi).  The estimation of the risk ratio parameter exp(ψH) is based on the 
partial likelihood of Cox.  The logrank test, which is equivalent to the partial 
likelihood score test, can be used for testing the causal null hypothesis of no 
treatment effect.129 
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What this means in practical terms for the HIP PRO analysis is that, if there is 
truly no causal (protective or harmful) effect of hip protectors on hip fractures, then 
the ITT analysis provides an unbiased estimate of this effect.  But what if hip 
protectors actually do provide protection against hip fractures in the true study 
population?  In that case, under non-adherence, the ITT analysis and the as-treated 
analysis will both fail in estimating the true causal effect of hip protectors on hip 
fractures, because, as noted above, neither approach guarantees exchangeability of 
the study groups.  Three relatively new methods in the epidemiology literature 
correct for non-adherence in randomized studies, and can provide unbiased effect 
estimates: instrumental variable analysis (which comes from the econometric 
literature)120-121, 130, marginal structural models (using inverse probability of treatment 
weights) by Robins et al122, 124, 131-132, and structural nested models, also by Robins 
et. al.123-124, 133 
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EFFICACY VERSUS EFFECTIVENESS 
 
 Our motivation to correct for the non-adherence in the HIP PRO study is to 
estimate the effect of treatment for all persons who receive the therapeutic agent to 
which they were assigned (i.e., hip protectors or no hip protectors).  This estimate, 
which measures the biologic action of hip protectors among adherent participants, 
has been conceptualized as estimating ‘biologic efficacy’ by Sommer and Zeger134 
and ‘method-effectiveness’ by Sheiner and Rubin.135  We will consider this estimate 
as simply defining the ‘efficacy’ of treatment.  An alternative estimate which is often 
of interest in randomized studies is the effect of treatment assignment, sometimes 
referred to as an estimate of ‘use-effectiveness’ 135 or ‘programmatic 
effectiveness’134, but which we will consider simply as an estimate of ‘effectiveness.’  
In a randomized study, when adherence is complete, the estimate of efficacy equals 
the estimate of effectiveness. 
 In the presence of important non-adherence investigators have traditionally 
undertaken a number of alternative strategies to analyze data from randomized 
studies.  One somewhat simplistic approach that is sometimes undertaken to 
account for non-adherence is to adjust for the non-adherence.  This adjustment 
apparently should allow for the estimation of the effect of treatment (i.e., 
randomization) on the outcome.  Unfortunately, this approach is incorrect because 
stratification on intermediate variable (e.g., adherence, which is on the causal 
pathway) can lead to biased estimates of the direct effect of randomization on the 
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outcome.  To understand why, consider that adherent patients may be different from 
non-adherent patients on characteristics that affect both the self-selection for 
treatment and the outcome.  For example, in the hip protector studies, individuals 
who are sicker and at higher risk for hip fracture may be more likely to wear hip 
protectors.  When this is true, a comparison of adherent and non-adherent patients 
will be invalid.  Because of problems of this sort, investigators often rigidly follow ITT 
analysis in randomized studies.121 
An ITT (as randomized) analysis compares observed outcomes according to 
initial group assignment.  ITT analyses provide valid estimates and associated tests 
and confidence intervals for the effect on outcome of assignment to therapy (i.e., for 
effectiveness).135  However, for estimating efficacy, the ITT estimate suffers bias 
toward the null in proportion to the degree of non-adherence.136  This happens, for 
example, when hips assigned to wear protectors do not wear them (for whatever 
reason), so that the group originally assigned to wear protectors are now comprised 
of adherent and non-adherent hips.  The dilution effect of non-adherent hips makes 
it difficult to estimate efficacy with conventional ITT analyses and makes it 
particularly difficult to answer the question of how large the treatment effect might 
be.136   
  Despite the limitation of ITT analysis to estimate efficacy under non-
adherence, the ITT estimate has become the gold standard for analyzing data from 
randomized studies.  One of the strengths that is often posited by advocates of the 
ITT analysis is that only the original randomized assignment is guaranteed, in 
expectation, to be un-confounded, and so the only inferences that can be trusted 
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must be based on the original assignment.135  This is an important point that is worth 
further consideration.  However, it must be considered in the context of what 
question the ITT analysis is designed to address.  Recall that the ITT analysis is 
designed to evaluate outcome differences associated with the prescription of 
alternative treatments, not of the treatment themselves.  Sheiner et al135 argue 
convincingly that the ITT analysis, in the presence of non-adherence, can only 
validly determine whether, under usual conditions of use, the new treatment 
produces net benefit.  So, an ITT analysis does not answer the question of whether 
the therapy (e.g., hip protectors) could help if utilized; rather, it answers the question 
of whether the therapeutic ‘policy’ of providing hip protectors actually helps.  Even in 
the limited subset of studies which evaluate the effectiveness of the intervention, 
however, an ITT analysis is only valid if the trial design ensures that most of the 
features potentially affecting adherence resembles those prevalent in practice.135  
When this is not true, the results of the trial will only have internal validity (i.e., 
comparisons between the two treatment arms are unbiased for a population that is 
similar to the one that has been particularly selected for a given trial); however, it will 
not have external validity (i.e., the results of the trial do not apply broadly to the 
general population).137 
 While acknowledging that the ITT analysis does not provide a valid estimate 
of the strength of treatment (under non-adherence), some scientists argue that it 
does provide evidence of the existence of efficacy.  This is because the ITT estimate 
is unbiased for both efficacy and effectiveness (because they are both zero), and an 
alpha-level test of effectiveness is equal to an alpha-level test of efficacy.  Following 
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this logic, in the scenario where non-adherence is substantial and the ITT estimate is 
downward biased for efficacy, an ITT analysis would suffer some loss of power since 
it would fail to reject the null hypothesis when it is false.  However, this loss of power 
could easily be overcome by choosing a larger study size.135   
The problems with the above line of reasoning are two-fold.  First, in many 
situations, the extent of non-adherence may be unknown a priori and it may be 
difficult to determine an adequate sample size to account for non-adherence.  In this 
situation, confusion can result about what future course of action should be 
undertaken if the null hypothesis of no treatment effect cannot be rejected.  If the 
intervention is not efficacious, then it should be abandoned.  Alternatively, if the 
intervention failed because of non-adherence then efforts should be taken to 
discover and address the reasons for non-adherence.  The ITT estimate alone 
provides no guidance about which course of action is best.  Second, even if the level 
of non-adherence in the proposed study is correctly anticipated and an adequate 
sample size is determined, an ITT analysis will only provide evidence for the 
existence of efficacy.  But, in most situations, we are also concerned about an 
unbiased estimate of the strength of treatment.  For example, if we are interested in 
choosing among alternative treatments, we would obviously be interested in which 
treatments are more or less beneficial.135  The downwardly biased estimate for 
efficacy which is provided by an ITT analysis (under non-adherence) prevents us 
from making an informed decision among alternative treatments. 
 When non-adherence is appreciable, some investigators have undertaken a 
comparison of participants according to treatment received.  The two most 
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commonly used methods include ‘as-treated’ and ‘per-protocol’ analyses.  Both of 
these methods are widely distrusted because they do not use the correct 
assumption of initial randomization and because their effect estimates and tests of 
the null are arbitrarily biased when adherence is non-random (e.g., when the 
baseline risk of the outcome is different for adherent and non-adherent 
participants).138  However, as Sheiner and Rubin135 and Korohonen et. al.129 have 
pointed out, both of these methods correctly model the actual assignment 
mechanism, and, under additional assumptions, may yield valid estimates of efficacy 
for some subset of the study population.  As such, both of these methods deserve 
closer examination. 
 Both the as-treated and per-protocol analyses group participants according to 
their received treatment, but in slightly different ways.  The per-protocol analysis 
discards entire records of patients who go off treatment.  The main problem with this 
approach is that the comparison groups are now based on post-randomization 
events affected by treatment and prognostic factors, including non-adherence.136  
One can imagine a situation in which participants with poorer prognosis are removed 
from the treatment group because they are less able to adhere to the assigned 
intervention.  Under this typical scenario for a per-protocol analysis, the effect 
estimate will be biased away from the null (i.e., the intervention will appear to be 
more efficacious than it truly is).  Because the per-protocol analysis is extremely 
sensitive to even small sources of bias136, it should generally be avoided.  However, 
it is worth considering what question the per-protocol analysis seeks to answer.  
Sheiner et al suggest that the per-protocol analysis answers the question: “What are 
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the differences between average outcomes among adherent participants in the 
treatment arm and average outcomes among adherent participants in the control 
arm?”135  Rather than contrasting two groups that are deemed exchangeable 
(because of randomization), the per-protocol analysis contrasts the expected 
outcomes in two different populations.  If one can imagine scenarios where non-
adherence occurs at random (e.g., if all the non-adherence were attributable to 
pharmacy dispensing errors) then the per-protocol analysis addresses efficacy and 
the non-adherence simply decreases study power by eliminating some outcomes in 
the treatment group.135  In typical randomized studies with non-adherence, however, 
it is difficult to justify random non-adherence.  In such situations, the effect estimates 
from a per-protocol analysis will be biased and tests of the null may be non-zero 
even if there is no effect of treatment on the outcome.136 
 The as-treated analysis, in contrast to the per-protocol analysis, uses all of 
the study data by redefining non-adherent participants in the treatment arm as 
control participants.  This approach attempts to deal with the loss of power seen in 
the per-protocol analysis, but at the cost of blurring the definition of adherence to 
treatment.  In addition, it does nothing to clarify the confusion in inference that 
occurs because of the post-randomization redefinition of treatment groups.  The as-
treated analysis compares outcomes in two different populations:  adherent 
participants receiving treatment and those who are in the control group because of 
assignment or because of non-adherence.135  The as-treated approach can be 
misleading when outcome dependent non-adherence is present.129  The direction of 
the bias will depend on the characteristic of non-adherent participants who are 
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reclassified as controls.  If worse prognosis participants tend to be non-adherent 
then the bias will be away from the null; conversely, if ‘switchers’ are better 
prognosis participants, then the effect estimates will be attenuated.  Korohonen et. 
al. provide simulation results showing that an as-treated analysis is valid when non-
adherence occurs at random.129  As we have pointed out earlier, however, this rarely 
occurs in real world settings.  Consequently, scientists should be cautious when 
using an as-treated analysis to estimate efficacy. 
 We have seen that the three standard approaches to estimate efficacy are 
often biased under non-adherence because they rely on incorrect assumptions.  The 
ITT analysis assumes that all individuals assigned to treatment are continuously 
exposed to the intervention during follow-up.  The per-protocol and as-treated 
estimators avoid this pitfall by modeling actual assignment to treatment; however, 
they make a strong assumption that adherence is random.  The ITT is preferred 
when estimating efficacy because of the apparent lack of an acceptable alternative 
approach to avoid selection bias.134  We contend that valid alternatives to the ITT 
analysis do exist, but these alternative methods require an accurate measurement of 
adherence, of relevant concomitants, or both.  In the following section we describe 
one of these methods, an instrumental variable (IV) approach, which estimates the 
magnitude of the treatment effect (efficacy) among adherent patients in a 
randomized study setting.  This approach respects the original randomization and is 
valid even when adherent participants have a different baseline risk than non-
adherent participants.139 
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NON-ADHERENCE CORRECTION USING INSTRUMENTAL VARIABLES 
 
Introduction 
 
Instrumental variable (IV) analysis has had limited application in the 
epidemiology literature because this technique requires the existence of one or more 
variables that are at least modestly associated with the treatment variable but have 
no direct effect on the outcome variable of interest.137  Here, we describe  a non-
parametric IV method which can be applied to randomized studies with a 
dichotomous exposure and a dichotomous outcome.  In the context of a randomized 
clinical trial, treatment assignment Z (i.e., randomization) can provide an almost 
perfect instrumental variable for confounder control.  Z is a variable that, we hope, is 
highly correlated with the receipt of treatment (X) and it’s only effect on the outcome, 
Y, is through X (i.e., there is no direct effect of Z on Y, or effects that are mediated 
by variables other than X). 
 The goal of the analysis is to compare the adherent participants in the 
intervention arm to an inferred control group chosen to eliminate bias.134  The 
resulting estimate of efficacy in adherent participants has been variously called a 
local average treatments effect (LATE) or the complier-average causal effect 
(CACE) of treatment.140  In the current analysis, we specifically seek to apply the IV 
method to the HIP PRO study to estimate efficacy in an adherent sub-group of the 
total study population.  Because of the historical development of terminology in the 
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IV literature, we will refer to ‘adherent’ participants as ‘compliant’ participants for the 
duration of this discussion. 
For the HIP PRO study, the directed acyclic graph (DAG)127, 141-142 below 
shows a causal diagram that relates treatment assignment (Z) to treatment received 
(X) and to the outcome (Y).  A variable (Z) is an instrumental variable for the causal 
effect of (X) on (Y) if its average effect on X is nonzero, it satisfies the exclusion 
restriction and the monotonicity assumption, is randomly assigned, and the stable 
unit treatment value assumption holds.140  These assumptions are discussed in 
greater detail below: 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 – Directed acyclic graph (DAG) relating treatment assignment (Z) to 
treatment received (X) and to the outcome (Y) 
 
 
The above causal diagram allows us to conveniently discuss the assumptions of an 
IV analysis.  First, we begin with the assumption that the potential outcomes for each 
participant i’s hip j are unrelated to the treatment status of other hips.  This 
assumption, also known as the stable unit treatment value assumption (SUTVA) is 
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important for most epidemiologic analyses and it ensures that the outcomes in the 
analysis are independent.  Because no individual could have more than one hip 
fracture in HIP PRO, we do not concern ourselves with clustering of hip fractures 
within individuals.  And, because the intra-class correlation coefficient (ICC) between 
nursing homes was small, we posit that the impact of clustering within nursing 
homes was negligible and that the SUTVA assumption was approximately met in 
HIP PRO.  The satisfaction of this assumption is important because the relatively 
straightforward IV analysis outlined below is not valid when SUTVA is violated.140 
 The second assumption for an IV analysis is that treatment assignment (Z) is 
randomized and that any effect of (Z) on the outcome (Y), must be through effect on 
treatment actually received (X) (see the causal diagram above).  This assumption, 
also known as the exclusion restriction, has certain implications.  First, this 
assumption implies that randomization (Z) is independent of any measured and 
unmeasured set of covariates (U) that might affect both the receipt of treatment (X) 
and the outcome (Y).  Because treatment assignment is randomized we would 
expect that there are no confounders that would confound the (Z)-(Y) relationship.  
In practice, this is unverifiable from the data but is assured to be true (in expectation) 
as the sample size of the trial becomes large.  The exclusion restriction also implies 
that the treatment that was actually received is substantially associated with 
randomization, but not fully determined by assignment Z.  In the HIP PRO study this 
appears to be true because only hips randomized to treatment actually wore the hip 
protectors.  Finally, the exclusion restriction implies that the assignment to treatment 
(Z) is independent of the outcome (Y), given treatment actually received (X) and (U).  
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This suggests that randomization (Z) has no direct effect on the outcome (Y), but, 
again, this cannot be verified from the data.120-121 
 The final two assumptions for an IV analysis relate to the composition of the 
study population.  Under SUTVA and the exclusion restriction, the study population 
from a randomized study can be conceptualized as comprising four potentially latent 
class of participants (these latent classes have also been labeled as principal strata 
by some authors): (1) Would-be compliers are those individuals who would take 
whatever treatment is assigned, (2) Always-takers are those who would take the 
treatment no matter what their assignment, (3) Never-takers are those who would 
not take the treatment no matter what their assignment, and (4) Defiers are those 
who would take the treatment opposite from their assignment regardless of the 
treatment they were assigned.143  Under this classification, an IV analysis assumes 
that there are at least some would-be compliers.  Finally, we assume that there are 
no individuals who do the opposite of their treatment assignment.  With these last 
two assumptions we are left with only compliant participants, always-takers, and 
never-takers, and so there are six possible combinations of participants, three in 
each treatment arm.    
It should be noted here that even under all four of the assumptions outlined 
above, we are unable to identify specific compliant participants for whom we can 
identify the average treatment effect.  We can only identify the local average 
treatment effect for ‘would-be’ compliers.  This effect is not the average treatment 
effect for the entire study population or even a sub-population identifiable from 
observed values.  Rather, this is the effect for a hypothetical population of 
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participants who would have complied with treatment if they had been assigned to 
treatment.120 
If we are interested in linear relationships, then, under the conditions outlined 
above for an IV analysis, we can write the relationship between the randomization 
(Z) and the outcome (Y) as a product of the (Z)-(X) and the (X)-(Y) associations121 
AssocZY = AssocZX * AssocXY, and then solve this equation for the (X)-(Y) 
association.  This association is important when considering non-adherence in the 
HIP PRO study – note that although the observed (X)-(Y) association can be 
confounded, the (Z)-(X) and the (Z)-(Y) associations cannot be confounded because 
(Z) is randomly assigned.  As a result, we can obtain an unbiased estimate of the 
effect of (X) on (Y) with the following ratio: 
 
E[Y | Z=1] – E[Y | Z=0]    /    E[X | Z=1] – E[X | Z=0] 
 
This is the estimated effect of treatment received (i.e., AssocXY) and has sometimes 
been referred to as Bloom’s IV estimator.128  In essence, what we are doing here is 
taking the entire effect of (Z) on (Y) and factoring out the effect of (Z) on (X), to arrive 
at the average effect of (X) on (Y).  Looked at another way, the denominator of the 
estimator above can be thought of as the intention-to-treat effect.  If adherence is 
100%, the denominator of the estimator will equal 1.0 and the effect of (X) on (Y) will 
equal the effect of Z on Y.  However, as non-adherence increases, the denominator 
allows for the unbiased adjustment of the ITT effect.121 
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 There are several alternative but equivalent strategies to estimate the effect 
of treatment received (X) on the outcome, hip fractures (Y).  This effect estimate can 
be obtained by implementing a two-stage least squares (2SLS) algorithm (i.e., first 
regressing X on Z and then regressing Y on the predicted value of X obtained from 
the first regression).128  An alternative strategy is a two-stage procedure described 
by Nagelkerke.144 These authors also begin by regressing X on Z, but, rather than 
using the predicted values in the second stage, they use the residuals.  In the 
second stage, a regression of Y on both Z and the residuals from the first stage will 
yield an unbiased estimate of the effect of treatment received. 
 Although the two methods described above are attractive options, we seek to 
produce a measure of effect that is comparable to the rate ratio obtained from the 
HIP PRO study.  To that end, in the next section we implement a non-parametric IV 
method developed by Cain et. al. which estimates the rate instead of the risk of hip 
protectors.145 
  
Methods and Results 
 
 For the IV analysis, we use the following notation.  Subscript i indexes 1 to 
N=1042 participants in the first HIP PRO study, and subscript j indexes either the left 
(=0) or right (=1) hip.  Adherence visits occurred three times a week, across all 
nursing shifts.  For the purpose of the current analysis, and for consistency across 
subsequent analyses, we collapse the adherence visits into two week increments.  
Defined in this manner, we used subscript k to denote the 1 to Ki,j two-week 
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adherence visits.  The maximum number of visits was 54.  Subscript x indexes the 
actual wearing of the hip protectors during a two-week period, where a protected hip 
was considered compliant when wearing the hip protector in more than 75% of 
adherence visits in that two-week time period.  Once a protected hip became non-
compliant in any two-week time period, then that hip was considered as non-
compliant in all subsequent visits.  Note that unprotected hips were always compliant 
(x=1) because no hip assigned to the control arm of the study wore hip protectors.  
Subscript z denotes the randomization arm, where 1 indicates assignment to the hip 
protector arm and 0 the control arm.  Dijkxz=1 indicates that hip i,j experienced a hip 
fracture between visits k and k+1 while using therapy x in the randomization arm z, 0 
otherwise.  Tijkxz is the number of person-years that hip i,j contributed between visits 
k-1 and k while using therapy x under randomization arm z. 
 Under this notation, the total number of hip fractures occurring while using 
therapy x when randomized to treatment z, summed over hips and adherence visits, 
is:  
,1042 2
1 1 1
i jK
xz ijkxz
i j k
D D
= = =
= ∑ ∑ ∑  
The total number of person-years contributed while using therapy x under 
randomized treatment z, again summed over hips and adherence visits, is: 
,1042 2
1 1 1
i jK
xz ijkxz
i j k
T T
= = =
= ∑ ∑ ∑  
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We estimate the conditional probability of using therapy x under randomized 
treatment arm z, αxz = P(X=x|Z=z), by the proportion of person-time spent using 
therapy x under randomized treatment z,  αxz = Txz / T+z, where T+Z = 
1
0x=
∑  Txz. 
 Figure 2.2 depicts a tree diagram which shows the division of hip fractures 
and person-time, by randomized treatment arm, actual use of hip protectors, and 
potential hip protector use in the HIP PRO study.16  Our goal is to use the observed 
data in the second and third rows of the diagram to estimate, in the fourth row, the 
potential hip fractures and potential person-time that would have been observed in 
the alternate treatment arm.  We proceed by using the notation above to describe 
the data in the second and third rows.  There were a total of 38 hip fractures in HIP 
PRO during 1354 person-years of follow-up.   A total of D+1=21 hip fractures 
occurred during T+1=677 person-years in the protected arm of the study, while 
D+0=17 hip fractures occurred during T+0=677 person-years in the control arm.  In 
the treatment arm, there were D11=2 hip fractures during T11=146.54 compliant 
person-years; the remaining D01=19 hip fractures occurred during T01=530.46 non-
compliant person-years.  In the control arm hips were always compliant; as a result, 
the corresponding hip fractures and person-times were apportioned as follows: 
D00=17, T00=677, D10=0, T10=0.  The conditional probability of using therapy x=1 
under randomized treatment z=1, as noted previously, was estimated by the 
proportion of person-time spent using therapy x=1 (i.e., T11) under randomized 
treatment z=1 (i.e., T+1): α11 = 146.54 / 677 = 0.22.  In a similar manner, we 
calculated α01 = 0.78, α00 = 1.00, α01 =0.00. 
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 The standard intention-to-treat analysis compares rates between the two 
treatment arms, without considering that overall adherence in HIP PRO was only 
74%.  The ITT estimator of the average effect of treatment can be calculated from 
Figure 2.2, according to the following formula: 
11 01 1
11 01 1
10 00 0
10 00 0
11 01
10 00
21
677 1.2317
677
D D D
T T T
ITT
D D D
T T T
α α
β
α α
+
+
+
+
     × + ×     
     = = = =
     × + ×     
     
 
The 95% confidence interval for this point estimate is calculated in the usual way, 
using the standard error of the rate ratio:  
1 1 1 1. (ln( )) 0.32
21 677 17 677
s e RR = − + − =  
The 95% confidence for the ITT effect of treatment assignment was (0.65, 2.32).   
Note again that the ITT effect estimate is biased for treatment received.  What 
we are interested in is an IV estimator which compares rates between the two 
treatment arms among ‘would-be compliers’, those who would have used hip 
protectors if assigned to wear protectors and those who would not have used hip 
protectors if not assigned to wear them.  The distinction between an ‘observed 
complier’ and a‘would-be’ complier is an important one.  A ‘would-be complier’ is an 
individual who would comply under both treatment regimes, while an ‘observed 
complier’ is compliant only under the treatment actually assigned.  The crux of the 
problem is that we only observe the compliance status with the assigned treatment 
for each individual; we don’t know the compliance status that would have occurred if 
assigned to the alternate treatment.143  The appeal of the IV method is that it allows 
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us to estimate the compliance status in the ‘would-be compliers.’  Specifically, for the 
HIP PRO study, the IV approach that we use allows us to estimate the rate of hip 
fractures in the ‘would-be compliers’ in both treatment arms. 
 Next, we describe how to obtain the ITT effect estimate from data in Figure 
2.2.  The following heuristic explains why this approach works.  The rate of hip 
fractures in the treatment group who use the treatment is an unbiased estimate of 
the rate of hip fractures in ‘would-be compliers’ and the ‘always-takers.’  The 
‘always-takers’ are actually non-compliers because, if they had been assigned to the 
control arm, they would have worn hip protectors.  Note that the rate of hip fractures 
in the control group who adopt the treatment is an unbiased estimate of the rate of 
hip fractures in these ‘always-takers.’  By using information in the control arm of the 
study for ‘always-takers’, we are able to factor out the effect of ‘always-takers’ in the 
treatment arm.  The difference is an unbiased estimate of the rate of hip fractures in 
the ‘would-be compliers.143 
Following Cain et al145 we calculate the person-time in the fourth row of 
Figure 2.2 before calculating the number of events.  We use the conditional 
probability of using therapy (i.e., αxz) in the alternate treatment arm to determine the 
potential person-time in ‘would-be compliers.’  Consider the 146.54 person-years of 
those individuals who were randomized to wear hip protectors and actually wore 
them.  We use the conditional probability of using therapy (α01) and not using 
therapy (α00) in the control arm of the study to calculate the potential person-time.  
Recall that there were no hips that were non-compliant in the control arm; as a 
result, α01=0.00 and α00=1.00.  The potential person-time for the ‘would-be 
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compliers’ (i.e., the Xz=0=0 group) is then 146.54 = 1.00 * 146.54.  This represents 
the amount of person-time in the treatment arm of the study (for those who actually 
used therapy) that would have been compliant person-time if assigned to the control 
arm.  The remaining person-time is apportioned to the ‘always-takers’ (the Xz=0=1 
group).  In the case of the HIP PRO study, this was 0 person-years.  The person-
time for those who were non-compliant does not need to be partitioned and is simply 
carried forward to the fourth row.  This person-time (530.46 person-years) is 
allocated to the ‘never-takers’ – the third hypothetical (potential) group in the 
randomized arm of the study.  We proceed in a similar manner to allocate person-
time to the ‘would-be compliers’ (Xz=1=1) as α11 * 677 PYs = 0.22 * 677 PYs = 
146.54 PYs, in the ‘never-takers’ (Xz-1=0) as α10 * 677 PYs = 0.78 * 677 PYs = 
530.46 PY. For the ‘always-takers’ the number of person-years are carried forward 
to the fourth row. 
 To determine the number of hip fractures which should be allocated to each 
of three groups of patients, we use the rate of hip fractures in the alternate treatment 
arm.  For example, to determine the total number of hip fractures allocated to the 
‘always-takers’ group in the treatment arm of the study, we multiply the total person-
time occurring in compliant patients in the treatment arm by the rate (0 / 0 PYs) in 
the non-compliant ‘ always-takers’ in the control arm.  This is equal to 0 = (0 / 0 PYs) 
* 0 PYs.  The remaining hip fractures (2-0=2) are allocated to the ‘would-be 
compliers.’  In the treatment arm, the hip fractures occurring during non-compliant 
person-time (i.e., 19 hip fractures) are not partitioned; they are all allocated to the 
‘never-takers.’  Similarly, in the control arm, the number of hip fractures in the ‘never-
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takers’ is equal to the rate of hip fractures in the ‘never-takers’ in the treatment arm 
multiplied by the person years in the ‘never-takers.’  Note that this is equal to 19 = 
(19 / 530.26 PYs) * (530.46 PYs).  However, this is greater than the number of hip 
fracture in compliant hips in the control arm of the study.  This is not possible, and, 
because we cannot determine the number of hip fractures for ‘never-takers,’ we also 
cannot determine the number of hip fractures in the ‘would-be compliers.’  
Consequently, we cannot determine the IV estimate of the rate ratio, which is a 
comparison of the rate of hip fractures in ‘would-be compliers’ in the treated versus 
untreated groups.  Note that the potential outcomes in the ‘would-be compliers’ in 
the control arm remained missing; as a result, the IV rate ratio was also missing 
because:  RR = (2 / 146.55 PYs) / (? / 146.55 PYs) = ? 
 
Discussion 
 
One of the strengths of the HIP PRO study is that it collected detailed 
information on compliance during three weekly unannounced visits by compliance 
monitors.  This is in contrast to many randomized studies where the non-compliance 
is measured with much error.  When treatment received for study participants is not 
known with some level of accuracy, it can be difficult, if not impossible, to estimate 
treatment effects.  Also, treatment effects can be difficult to estimate if study 
participants can be non-compliant because they take an intervention that is not 
under study.  In the current IV analysis, we have an accurate measure of compliance 
in HIP PRO and we assumed that there were no interventions available other than 
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the hip protectors.  By study design, study participants were allowed to switch 
treatments only in one direction, from hip protectors to the control (i.e., no treatment) 
arm.144  In similar scenarios, the IV approach has been known, in other study 
settings, to provide a valid estimate of the effect of treatment received in the ‘would-
be compliers.’ 
In the HIP PRO study a simple IV method designed to estimate the rate ratio 
in ‘would-be compliers’ failed.  This may have been because of the HIP PRO study 
design, which resulted in equivalent person-time being allocated to both treatment 
arms and which had no observed non-compliant individuals in the control arm.  We 
attempted to obtain a rate ratio in the current analysis, to compare our results with 
the ITT rate ratio.  It is not clear whether the IV approach is feasible in all situations, 
on the rate ratio scale; this requires further investigation.  Beyond the fact that the IV 
approach failed to yield an effect estimate in the HIP PRO study, it should be noted 
that both the approach that we adopted and other standard IV approaches are 
poorly equipped to address this time-varying exposure.144  We now turn our attention 
to another approach for non-adherence correction, using inverse probability-of-
censoring weights, which account for the time-varying nature of exposure to hip 
protectors in HIP PRO. 
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Figure 2.2 Tree diagram showing division of hip fractures and person-time, by 
randomized treatment arm, actual use of hip protectors, and potential hip 
protector use, in the Hip Impact Protection Project (HIP PRO). 
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CHAPTER 3 
 
EFFECT OF HIP PROTECTORS USING INVERSE PROBABILITY OF 
CENSORING WEIGHTS (IPCWs) 
 
Introduction 
 
 In the United States more than 300,000 people aged 65 years or older are 
hospitalized as a result of hip fractures every year.6  The one-year mortality rate for 
individuals suffering a hip fracture can be as high as 33%29, 34, 94 and up to 40% are 
severely disabled or unable to walk independently two years after the event. 
Effective interventions aimed at reducing hip fractures, such as bisphosphonates, 
should prevent a substantial number of fractures.146  In practice, however, adherence 
to these agents has not been optimal. Alternative approaches to hip fracture 
prevention, such as hip protectors, which fit over the trochanteric prominence, were 
designed to attenuate the peak impact force entering the proximal femur during a fall 
to the side, and, thus, address the proximate cause of hip fracture. As with other 
interventions,15, 30, 60 randomized studies of hip protectors have demonstrated mixed 
results, possibly due in part to varying adherence.   
In this paper, we describe the application of inverse probability of censoring 
weights (IPCWs)122, 132, 147-148  to correct for non-adherence in the Hip Impact 
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Protection PROject (HIP PRO), a multi-center, randomized, controlled clinical 
trial of hip protectors to prevent hip fractures.16 The methods presented here are 
applicable to any intervention studies that suffer from less than complete adherence.  
 
Methods 
 
The Hip Impact Protection PROject (HIP PRO) 
 
 As described in greater detail previously, a total of 1042 residents from 37 
nursing homes (NHs)16, 125 were enrolled into the HIP PRO study between October 
2002 and October 2004 and contributed 676 person-years of observation over a 
maximum of 24 months. HIP PRO used a cluster randomization strategy, whereby 
all residents in a given NH were designated to wear an energy-absorbing and 
distributing hip protector on either the left or right hip. A dynamic enrollment 
procedure, taking into account differences in NH size, was designed to achieve an 
approximately equal allocation of residents into each arm of the study. After 
randomization, the left hip was protected for 587 (56%) residents and the right hip 
was protected for 455 (44%) residents. Written informed consent was obtained from 
individual NH residents with a Short Blessed Test (SBT)126 score less than 12 (no 
more than mild cognitive impairment) and from a designated responsible party 
otherwise. Each participating NH obtained Federal Wide Assurance from the Office 
of Human Research Protections, US Department of Health and Human Services. 
Institutional Review Board approval for the study was obtained by the three research 
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sites and the coordinating center. Resident safety was monitored every six months 
by an independent data and safety monitoring board.  
 At baseline and every six months after randomization, residents provided data 
on affect, cognitive, functional, and mobility status. Cognitively intact residents also 
provided information about fear of falling, perceived need for hip protectors, and 
body image. Research staff, on a weekly basis, reviewed resident charts, evaluated 
changes in resident behavior, and tracked calls made to a hip fracture hotline 
telephone number to evaluate falls and the presence of an incident hip fracture. Hip 
fractures were confirmed by a fracture adjudication committee masked to hip 
protector side. Research staff evaluated adherence in three unannounced visits 
each week, across all work shifts, including weekends. Residents who were non-
adherent in more than two of six such visits during the first two weeks after 
randomization (the run-in period) were withdrawn from the study (N=148). Overall 
adherence for the study was 73.8%, with adherence defined as the number of visits 
during which a participating NH resident was found to be correctly wearing the 
garment and protector divided by the number of research staff visits to the resident. 
For the current analysis, a resident was censored after the first instance in which her 
adherence was less than 75% in any two-week time period after randomization. 
Sensitivity analyses substituted values of 67% and 50% for the value of 75% in the 
definition of non-adherence. 
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Statistical Analysis 
 
IPCWs were calculated by modeling the probability of ceasing to comply with 
the protocol-dictated wearing of hip protectors, given the subject’s observed data up 
to that point in time. Weighting the ITT analysis with IPCWs corrected for the 
variability in adherence over time. 
To calculate the IPCWs, we used the following nomenclature. Let subscript i 
index 1 to N=1042 patients and let j denote an individual’s left (=0) or right (=1) hip.  
Further, because we measured time in two-week increments from the start of follow-
up, let k index 1 to a maximum of k=52 two-week periods after randomization. Let 
Xij=1 indicate that hip j for a given NH resident was randomized to wear a hip 
protector, and 0 otherwise. Let Dijk be an indicator of first hip fracture in the ith NH 
resident’s hip j, during time period k, so that Dijk=1 if a NH resident’s hip j 
experienced a hip fracture during time period k, and 0 otherwise. Let Cik=1 denote 
that a NH resident stopped wearing a hip protector and was censored during time 
period k, and 0 otherwise. Let Vi0 denote a set of individual-level and NH-level 
covariates measured at baseline. For the present analysis, Vi0 consisted of resident 
age, race (white/other), marital status (never married, married, widowed, 
divorced/separated), osteoporosis history (yes/no), cognitive status (based on the 
SBT126: normal/minimal impairment (SBT=0-8), moderate impairment (SBT=9-19), 
severe impairment (SBT≥20)), NH size, NH for-profit status, and an indicator of 
whether the NH allowed incontinent residents to wear hip protectors at night. In 
addition to all individual and NH baseline characteristics, let Vik also include the 
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individual-level, dichotomous, time-varying covariates bowel incontinence, bladder 
incontinence, cane use, and indicator variables for whether resident resisted care, 
was verbally abusive, displayed disruptive behavior, or had a fall. These time-
varying covariates were assessed every six months and missing values were filled in 
with previous non-missing values, if available. The time-invariant and time-varying 
variables were chosen based on a priori knowledge about the common causes of hip 
fractures and adherence, as well as on a concurrent analysis of the predictors of 
adherence in the HIP PRO study.125  
For protected hips the weights were defined as follows:  
 
SWijk =   P[Cijm=0| ijm=0,Xij=1] / P[Cijm=0| ijm=0,Xij=1,Vim-1]                               
 
where im represented a collection of covariates thought to be common causes of 
non-adherence and hip fractures based on a priori knowledge. Informally, SWijk 
represented the ratio of a subject’s probability of remaining uncensored up to time 
period k, calculated as if there were no time-fixed or time-varying determinants of 
censoring, divided by the subject’s conditional probability of remaining uncensored 
up to time period k.149 The true weights were unknown, but we estimated them from 
the observed data by fitting separate parametric regression models for the 
numerator and the denominator.150  For individuals censored due to non-adherence 
(i.e., Cij=1), zero weights were given to all follow-up time on or after censoring. The 
stabilized weights SWijk for unprotected hips were set to 1 for all individuals, at all 
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time points, because these hips were never exposed to hip protectors and therefore 
were always adherent with the assignment to be an unprotected hip.  
 The conditional probabilities for the numerator and denominator of the 
stabilized weights were fit using pooled logistic regression models for the discrete-
time hazard of censoring. Pooled logistic regression approximated the Cox model 
when the risk of hip fracture was small in any given person-time interval (in this 
analysis, the risk of hip fracture in any time period k was always less than one 
percent).151 The models for the numerator and the denominator of the weights, 
respectively, were of the form: 
 
logit P(Cik=0| ijk=0,Xij=1) = α0k + α 1 Xij,      
 
and 
 
logit P(Cik=0| ijk=0,Xij,Vik) = β0k +  β1 Xij  + β2 Vik,      
 
where α0k and β0k represented terms for the time specific intercepts (which we 
modeled as restricted cubic splines,152 with four knots at the 5th, 35th, 65th and 95th 
percentiles for the number of time periods since the baseline visit), and 2 was the 
transpose of the column vector of log hazard ratios for the components of the 
covariate history matrix Vik. 
We considered three alternative censoring mechanisms. In the first 
mechanism , we censored NH residents in any time period after their adherence 
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was less than 75%. This cut-point was less than full adherence but was felt to be 
appropriate because the overall adherence for the HIP PRO study was 74%. In 
practice, because there were on average 6 adherence visits in any given time 
period, individuals were censored when their adherence was less than 5 out of 6 
visits (83%). The second mechanism  censored individuals after their adherence 
first became less than 67% in any given time period (in general, adherent at 3 or 
fewer out of 6 adherence visits). The final censoring mechanism  censored 
individuals after their adherence first became less than 50% in any given time period 
(in general, adherent at 2 or fewer of 6 visits).   
 We considered four alternative sets of time-invariant and time-varying 
covariates for inclusion in the denominator model of the stabilized weights. In the 
main analysis and in the three sensitivity analyses, we included the time-fixed 
covariate of baseline age, race, marital status, osteoporosis history, and cognitive 
status, as well as the following time-varying dichotomous variables which were 
measured every six months: bowel incontinence, bladder incontinence, cane use, 
resisting care, verbally abusive, disruptive behavior, and recent fall. Covariates at 
the NH level were nursing home size, for-profit status, and a dichotomous variable 
indicating whether NH allowed incontinent residents to wear hip protectors at night.  
In sensitivity analyses, we separately considered adding body mass index (BMI) and 
educational status, because these covariates were considered potential common 
causes of non-adherence and hip fractures.  In addition, in the third sensitivity 
analysis, we considered adding both BMI and educational status to the denominator 
model of the stabilized weights. 
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 Educational status, a time-invariant variable that was measured at baseline, 
was missing for 26% of participating NH residents. We constructed inverse 
probability weights for missing education in a fashion similar to that used for 
constructing IPCWs.  Specifically, we defined stabilized weights to correct for 
missing education as follows: 
 
SWijk =   P[Mijm=0|Xij] / P[Mijm=0|Xij,Zim] ,                              
 
where Mijm=0 denoted that educational status was not missing for subject i’s hip j at 
time k, Xij indicated that a hip was protected or not, and Zik represented the set of 
known characteristics that theoretically explain the ‘missingness’ of education. This 
set included all the individual-level covariates specified earlier, excluding 
osteoporosis history and cane use. In sensitivity analysis, where we included 
educational status as a common cause of non-adherence and hip fractures, we 
multiplied censoring weights by the weights for missing education and ran the 
primary analysis in the subset of individual time periods where the resident was 
continuously adherent and had non-missing educational status. For all other 
covariates with less than 3% missing data, we replaced the missing data with the 
mode from the non-missing distribution of that variable. 
 We fit weighted pooled logistic models for the risk of hip fractures, for all 
different censoring mechanisms and sets of covariates. These models had the form: 
 
logit P(Dijk=1| ijk-1) = β0j + β1  ijk,                 
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where Dijk=1 indicated that subject i incurred a hip fracture in hip j, during time period 
k, β0j again represented time specific intercepts, and 1 represented the effect of hip 
protectors. Weighting each subject’s contribution by the stabilized weights created a 
pseudo-population that accounts for non-adherence. 1 provided an estimate of the 
log causal rate ratio, comparing the rate of hip fractures in protected hips, had, 
possibly contrary to fact, all protected hips remained adherent, to the rate of hip 
fractures in unprotected hips. Confidence intervals for the inverse probability of 
censoring weighted estimators were based on conservative robust variance 
estimates.153 All analyses were conducted using SAS version 9.1 software (SAS 
Institute, Inc., Cary, North Carolina). 
 
Results 
 
 The majority of the 1042 men and women making up the study population 
were composed of older white females with severe cognitive impairment.  In 
addition, most of the NH residents were widowed at baseline, while one-fifth had 
never been married.  A minority of the residents had experienced a fall in the 30 
days before the baseline visit, and a smaller proportion had a history of osteoporosis 
at baseline (Table 3.1). The NHs participating in the study were equally likely to be 
for-profit and not-for-profit, and most of the NHs allowed residents to wear hip 
protectors some or all of the time at night (Table 3.2). 
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After 676 person-years of follow-up, out of a total of 1042 enrolled NH 
residents, 38 (4%) experienced the primary outcome; 21 hip fractures occurred in 
protected hips and 17 hip fractures occurred in unprotected hips. The HIP PRO 
study was terminated early based on a recommendation from the data and safety 
monitoring board, due to a lack of efficacy and feasibility to detect a protective effect. 
The ITT analysis produced a matched rate ratio of 1.24 (95% confidence interval 
(C.I.) of 0.65 to 2.34), when comparing hips that were randomly assigned to be 
protected with the contra-lateral hips that were not protected.  Adjusting for 
clustering within NHs did not meaningfully change the results (RR=1.24 (95% C.I.: 
0.64, 2.37).16 Because NH residents were withdrawn after their first hip fracture, 
consideration of clustering of observations within individuals was ignored. 154   
 We replicated the results from the original published ITT analysis using 
pooled logistic regression and estimated a hip fracture incidence rate ratio of 1.24 
(95% C.I.: 0.65, 2.34), when comparing protected hips to unprotected hips.16 We 
present the results of our replication of the ITT analysis and three inverse 
probability-of-censoring weighted analyses in Table 3.3. 
 When we used the first censoring mechanism  to account for non-
adherence, in which we censored individuals the first time their adherence fell below 
75% in any given two-week period, and used all covariates previously specified, we 
found that the adherence corrected incidence rate ratio estimate was 0.55 (95% C.I.: 
0.13, 2.40).  More relaxed censoring mechanisms, where individuals were censored 
when adherence fell below 67% and 50%, also estimated a similar protective effect 
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of hip protectors in this study. These results suggest that the overall non-adherence 
in the study biased the ITT rate ratio.  
 In sensitivity analysis, we also included the individual-level, time-fixed 
covariate educational status in the set of Vij covariates when calculating stabilized 
weights. We included this covariate based on a priori knowledge that education was 
related to adherence and hypothesized that higher education status would have a 
direct negative effect on hip fracture incidence. In the HIP PRO study population, 
educational status was related to adherence but was only weakly related to the 
clinical endpoint. Inclusion of educational status resulted in incidence rate ratios that 
were similar to weighted models that did not include educational status, but had less 
precision.  With education added to the model, the estimated rate ratio was 0.62 
(95% C.I.: 0.14, 2.81) under censoring mechanism ,  0.61(95% C.I.: 0.13, 2.74) 
under , and 0.51 (95% C.I., 0.16, 1.63) under . When we separately included 
BMI in the set of Vij covariates we found no meaningful difference when compared to 
models that did not include BMI.  With BMI added to the model, the estimated rate 
ratio was 0.55 (95% C.I.: 0.13, 2.41) under , the rate ratio was 0.52(95% C.I.: 
0.12, 2.30) under , and was 0.72 (95% C.I., 0.28, 1.85) under .  When we 
added both education and BMI to the models used to calculate the stabilized 
weights, the estimated rate ratios were similar to those obtained from adding 
education alone, but the confidence intervals were wider. 
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Discussion 
 
 Using data from the HIP PRO study, we found substantial differences in 
results between the ITT analysis and analyses correcting for non-adherence with 
IPCWs.  The ITT analysis produced a relatively more precise estimate of the rate 
ratio in the direction of an adverse effect of hip protectors.  The results from the 
analysis employing IPCWs produced a much less precise estimate in the direction of 
a beneficial effect.   
 Some have suggested that the HIP PRO study design, in which only one hip 
was protected, allowed residents to fall preferentially onto the protected hip.  
However, it is unlikely that frail, elderly NH residents (71% with severe cognitive 
impairment) would have had the physical or mental ability to alter the direction of a 
fall.  Rather, the ITT results are biased toward and possibly beyond the null under by 
non-adherence.  The imprecise estimate provided by the inverse probability of 
censoring weighted approach, which corrects for non-adherence, supports the 
hypothesis that a biomechanically tested hip protector, if worn correctly, may reduce 
the incidence of hip fractures. 
Recent meta-analyses of hip protector clinical trials, including only high-
quality randomized studies, reported reductions of hip fracture incidence in nursing 
home residents only, but even the aggregated results were imprecise.79, 109  The 
more restrictive meta-analysis by Sawka and colleagues of NH residents included 
only three randomized studies in institutional settings  and reported a RR=0.56 (95% 
confidence interval: 0.31, 1.01), comparing hip fractures in individuals wearing hip 
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protectors and hip fractures in individuals not wearing hip protectors.79  In contrast, 
the meta-analysis by Parker and colleagues examined cluster randomized studies of 
hip protectors83, 88-89, 110, 118, 152, and produced an overall RR=0.77 (95% confidence 
interval: 0.62, 0.97).109  Although defined and measured in a variety of ways, the 
overall non-adherence of the studies included in the meta-analyses was substantial, 
ranging from 30% to 80%. Our adherence corrected results were similar to those 
obtained by Sawka. However, it should be noted that correction for non-adherence 
in the studies included by Sawka would have likely produced even stronger effect 
estimates than was noted in the meta-analysis.  
 As with most modeling techniques, we make certain assumptions when 
employing IPCWs to correct for non-adherence.  First, in constructing IPCWs we 
make a strong, un-testable assumption that there are no unmeasured confounders 
of adherence and hip fractures (this is also known as the exchangeability 
assumption).  The HIP PRO study collected a large number of individual-level and 
NH-level covariates that are risk factors for both non-adherence and for hip 
fractures.125 If these variables represent a close approximation of the full set of joint 
determinants of non-adherence and hip fractures then our final estimated effect 
estimate will be a valid approximation of the true effect estimate.   
Personal perceived health status and perceived need for hip protectors (e.g., 
because of a fear of falling) have been shown to be predictors of both adherence 
and hip fractures.84  Covariates that captured information on perceived health status 
and perceived need for hip protectors were collected in the HIP PRO study, but only 
for cognitively intact residents.  These covariates were not included in our final 
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model because the HIP PRO study population was overwhelmingly cognitively 
impaired; however, they should be included when correcting for non-adherence in 
hip protector studies of community-dwelling, cognitively intact individuals.  In 
sensitivity analyses, we included education in our final model based on the theory 
that education would be a common cause of non-adherence and hip fractures.  In 
the HIP PRO data, however, education was predictive of non-adherence, but only 
weakly related to hip fractures.  Including variables that are related to non-
adherence but unrelated to the outcome results in an increase of the variance of the 
final effect estimate, without decreasing bias.155  In contrast, including variables that 
are related to the outcome, but only weakly related to non-adherence, decreases the 
variance of the final effect estimate, without increasing bias.  Impaired vision has 
been shown to be related to hip fracture incidence.  Vision status was not collected 
for a majority of NH residents in the HIP PRO data.  If we assume that impaired 
vision is only weakly related to non-adherence, then exclusion of vision status from 
our final model would result in a less precise effect estimate.  Alternatively, if vision 
status is a strong confounder of non-adherence and the outcome, our final effect 
estimate would be biased because the exchangeability assumption would be 
violated.   
Second, we assume that the consistency assumption has been met.156-158  
This assumption requires that it should be clear how a certain level of exposure 
could hypothetically be assigned to a person actually exposed to a different level of 
exposure.  In randomized studies consistency is guaranteed, and, for the current 
analysis, we contend that the consistency assumption has been met since we have 
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a clear causal contrast, comparing hip fractures in hips that were protected against 
hips that were not protected. 
Finally, we assume that data on baseline educational status, race, history of 
osteoporosis, history of fall in last 30 days, marital status, and cognitive impairment 
are missing at random.  We used two approaches to deal with missing data.  For 
covariates with a low percent missing (<3%) we replaced the missing data with the 
mode of the non-missing data.  For one potential common cause of non-adherence 
and hip fractures with a high percentage (26%) of missing data, education status, we 
used inverse probability of missing weights to account for missing data.159  This 
approach to dealing with missing data was employed because it is consistent with 
the methods used to construct IPCWs for non-adherence.   
 Adherence has been a problem in randomized studies of hip protectors in 
NHs despite efforts to improve adherence, such as employing staff to encourage 
residents to wear hip protectors96. In the HIP PRO study, with arguably the most 
intense efforts to improve adherence, the overall adherence was only 74%. It is 
unlikely that future randomized studies of hip protectors will achieve overall 
adherence much greater than 74%. The ITT analysis of these future, hypothetical 
studies will compare those assigned to one treatment against those assigned to 
another treatment, without regard to treatment actually received, and incorrectly 
interpret the ITT results as the actual treatment effect.  Under non-adherence, this 
ITT analysis will be null-biased unless researchers obtain data on all important 
common causes of non-adherence and hip fractures and employ methods to correct 
for the non-adherence.  Anticipation of using methods such as IPCWs to correct for 
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non-adherence should also encourage investigators to increase the sample size 
requirements, when conceptualizing the design of studies. 
To our knowledge, the current analysis is the first application of IPCWs to 
correct for non-adherence in a gerontologic setting; however, the methods presented 
here can be widely employed to correct for non-adherence in any intervention study. 
In particular, the use of IPCWs could be valuable to data and safety monitoring 
boards when they are faced with difficult decisions regarding the termination of trials 
with sub-optimal adherence to an intervention like hip protectors. 
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Tables and Figures 
 
Table 3.1.  Selected Baseline Characteristics of 1042 Men and Women Randomized 
to Wear Hip Protectors on Either the Left Hip or the Right Hip in the Hip Impact 
Protection Project (HIP PRO). 
 
Characteristic 
Nursing Home Residents 
(N=1042)b 
Women 821 (78.8) 
Whitea 895 (85.9) 
Age, Mean (SD), year 85.3 (7.4) 
History of osteoporosisa 202 (19.4) 
History of fall in last 30 daysa 301 (29.2) 
Marital statusa  
  Never 193 (18.5) 
  Married 153 (14.7) 
  Widowed 631 (60.6) 
  Divorced/Separated 65 (6.2) 
Cognitive statusa,c  
  Normal / Mild impairment 151 (14.5) 
  Moderate impairment 147 (14.1) 
  Severe impairment 744 (71.4) 
aMissing data (<3% of total residents) replaced with mode of distribution. 
bRepresents total N(%), unless otherwise noted 
cCognitive status categories based on Short Blessed Test (SBT): normal / minimal 
impairment  (SBT = 0 – 8), moderate impairment (SBT = 9 – 19), severe impairment 
(SBT ≥ 20). 
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Table 3.2.  Nursing Home Characteristics of 37 Nursing Homes Participating in the 
Hip Impact Protection Project (HIP PRO). 
 
Characteristic 
Nursing Home  
(N=37)a 
For Profit 
 
18 (48.7) 
Total Number of Beds  
  < 100 Beds 4 (10.8) 
  100 – 149 Beds 13 (35.1) 
  150 – 199 Beds 12 (32.4) 
  >= 200 Beds 8 (21.6) 
Nursing Home Allows Hip Protectors to 
be 
       
 
  None 
 
6 (16.2) 
  Some 16 (43.2) 
  All 15 (40.5) 
aRepresents total N(%). 
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Table 3.3.  Intent-to-treat (ITT) and Inverse Probability of Censoring Weighted (IPCW) 
Analysis of 1042 Men and Women Randomized to Wear Hip Protectors on Either the Left 
Hip or the Right Hip in the Hip Impact Protection Project (HIP PRO). 
 
 
Analysis 
 
 
Hip Status 
 
No. Hip 
Fractures 
Person-
Years 
(PYs) 
Rate / 
100 
PYs 
 
Rate 
Ratio 
95% 
Confidence 
Interval 
Confidence 
Limit 
Ratio 
ITT Protected 21 676 3.11 1.24 0.65, 2.34 3.6 
 Unprotected 17 676 2.52 1 -  
IPCW1a Protected 2.1 146.5 1.41 0.55 0.13, 2.40 18.5 
 Unprotected 17 676 2.52 1 -  
IPCW2b Protected 2.3 159.8 1.41 0.52 0.12, 2.29 19.1 
 Unprotected 17 676 2.52 1 -  
IPCW3c Protected 5.6 331.3 1.69 0.67 0.26, 1.73 6.7 
 Unprotected 17 676 2.52 1 -  
aIndividuals censored in first time period in which adherence is less than 75%. 
bIndividuals censored in first time period in which adherence is less than 67%. 
cIndividuals censored in first time period in which adherence is less than 50%.
 
 
CHAPTER 4 
 
EFFECT OF HIP PROTECTORS ON FRACTURES USING A STRUCTURAL 
NESTED MODEL 
 
Introduction 
 
 Randomized studies of hip protectors have been plagued by an issue that 
affects many intervention studies, non-adherence with assigned therapy.88, 91, 93, 95-96, 
100, 112 These randomized studies have often been evaluated with intention-to-treat 
(ITT) analyses, which compare patients based on their assignment to treatment, 
regardless of their actual exposure to the intervention of interest. ITT analysis has 
qualities that make it appealing to scientists. First, under full adherence and no drop-
out, the ITT analysis provides a valid test of the null hypothesis that the treatment is 
ineffective and yields an unbiased estimate of a causal effect (i.e., a contrast in 
potential outcomes).127  Second, under non-adherence, an ITT analysis is 
conservative in the sense that it still provides a valid test of the null hypothesis that 
the treatment is ineffective, albeit at reduced power (which is a function of the 
amount of non-adherence).  However, by ignoring information on post-randomization 
non-adherence, ITT analyses estimate the effectiveness of treatment in a mixed 
population comprised of both compliers and non-compliers and, therefore, will 
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under-estimate the etiologic effect of treatment to the extent that the study 
population is comprised of non-compliers.138   
 Because of the problems inherent to ITT analyses of studies with non-trivial 
amounts of non-adherence, there have been calls to supplement the ITT effect 
estimate with adherence corrected effect estimates.136, 160 Structural nested models 
preserve the validity of the test of the null hypothesis and involve direct treatment 
group comparisons, with randomization used as an instrument for treatment.129, 136, 
161-162 In the current analysis, we employ this method to correct for non-adherence in 
the Hip Impact Protection PROject (HIP PRO).16  
 
Methods 
 
Study Population 
 
 HIP PRO was a multi-center, randomized, controlled clinical trial which 
evaluated the effect of hip protectors on hip fractures.16, 125 Randomization occurred 
at the nursing home (henceforth, home) level, with all residents of a home 
designated to wear the hip protector on either the right or left hip. Between October 
2002 and October 2004, 1042 residents from 37 homes contributed 676 person-
years of observation. Participants were seen weekly in homes that were in close 
proximity to three clinical coordinating centers, which were located in Boston, 
Massachusetts, St. Louis, Missouri, and Baltimore, Maryland. At baseline and every 
six months after randomization, residents provided data on affect, cognitive, 
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functional and mobility status. Institutional review boards approved the study 
protocol, and written informed consent was obtained for all residents. Resident 
safety was monitored by an independent data and safety monitoring board every six 
months.  Each participating home obtained Federal Wide Assurance from the Office 
of Human Research Protection, US Department of Health and Human Services. 
 The primary study endpoint in HIP PRO was a hip fracture, which was 
identified by weekly chart reviews, changes in resident mobility, and calls made to a 
hip fracture hotline telephone number. All hip fractures were confirmed by an 
independent fracture adjudication committee. Research staff evaluated the use of 
undergarments that were specifically designed for HIP PRO, as well as the correct 
positioning of the hip protector, in three weekly unannounced visits. These visits 
occurred across all work shifts and during weekends. Total adherence in HIP PRO 
was based on these visits and was defined as the number of visits during which 
residents were found to be correctly wearing the undergarment and the hip 
protector, divided by the total number of research staff visits. For the purpose of the 
current analysis, we followed residents in two week increments from the start of 
follow-up until they experienced a hip fracture, were lost to follow-up, or were 
administratively censored at the end of the study. For each two week period, we 
defined a resident as being adherent if she was correctly wearing the garment in at 
least 75% of research staff visits; otherwise, the resident was considered non-
adherent. 
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Statistical Analysis 
 
Individuals were indexed by i  and took values from i =1 to 1042, while j  
indexed hips and took values of 0 and 1. We used capital letters to represent 
random variables and lower letters to represent possible realizations of random 
variables. The treatment assignment indicator was denoted by ,R i j and took the 
value of 1 if an individual hip was randomized to wear the hip protector and 0, 
otherwise. ,i jΤ represented the time from randomization to hip fracture. The time on 
active treatment (adherent time) was denoted by ,Di j . In the placebo arm, ,Di j =0 for 
all ,i j  because hips in the placebo arm were never exposed to hip protectors.   
 The “potential failure time” was essential to our use of a structural nested 
model. The potential failure time for an observed participant was the time from 
randomization to hip fracture under a given treatment plan. One such potential 
failure time for each participant was the failure time that would have occurred if the 
participant had been unexposed throughout follow-up, say ,i jU . This potential failure 
time was considered a pre-randomization variable that existed for all participants but 
which was only partially observed. Indeed, we only observed the potential failure 
time for the treatment plan that the participant actually took (and that only under the 
consistency assumption and if the participant was not censored). To identify the 
point estimate for the effect of treatment, g-estimation of a structural nested failure 
time model leveraged a key assumption about the relationship between these 
potential failure times and randomization. The key assumption was that the potential 
 
 
99 
 
failure times ,i jU  were independent of the treatment arm indicator ,R i j . Under this 
assumption, using a model that linked observed treatment and failure times with 
potential failure times, g-estimation identified the parameter value ( Ψ ) at which the 
distribution of potential failure time given no treatment in the experimental arm was 
equal to the distribution of potential failure time given no treatment in the placebo 
arm.  This parameter value was an estimate of the effect of treatment. 
To link the potential failure time ,i jU , which was only observed for those never 
treated, with the observed treatment history and failure time, we used the 
accelerated failure time (AFT) model of Cox and Oakes.163-164 We defer the 
complication of censoring. The AFT model, a linear model for log failure times, 
allowed us to estimate the effect of treatment by parameterizing a relationship 
between a partially observed baseline quantity and observed event times, thereby 
allowing inference based on randomization. The measure of association in a 
structural nested failure time model was the survival time ratio. We estimated the 
survival time ratio by comparing the potential failure time corresponding to always 
exposed with the potential failure time corresponding to never exposed.165-166   
 For individual hips that experienced a hip fracture, we used their observed 
failure time to determine their potential failure time by using the following strong 
version of the structural AFT model129, 167: 
 
,* *
i,j 0 ,U (Ψ ) =   exp[ ( )]i j
T
i jR t dt∫ Ψ ×  
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This deterministic AFT model assumed that, for each hip, the potential failure time 
under no treatment, ,i jU , may be computed as a function of the randomization 
indicator, ,R i j , the observed failure time ,i jΤ , and a scalar parameter 
*Ψ .  *Ψ was an 
unknown parameter to be estimated, as described above.  The structural AFT model 
quantified how treatment-free survival time was contracted or extended by a factor 
exp(- *Ψ ), the survival time ratio.  A positive value of *Ψ  would indicate that constant 
exposure to hip protectors would decrease the time to hip fractures by exp(- *Ψ ) (i.e., 
treatment is harmful), when compared to the unexposed, while a negative value of 
*Ψ  would denote that constant exposure to hip protectors would increase the time to 
hip fractures (i.e., treatment is beneficial).  When *Ψ =0, there is no effect of 
treatment on survival time. 
 We estimated *Ψ  with g-estimation, a test-based procedure. This procedure 
checked for an association between ,R i j and a hypothesized value , ( )i jU Ψ of the true 
but unknown potential treatment-free failure time.123, 168 Note that we were able to 
compute , ( )i jU Ψ for a range of hypothesized, plausible values of Ψ  (e.g., -3 < Ψ  < 
3, by increments of 0.02) using the observed data ,{ , }i jT R in the AFT model. Using a 
finer search grid, say in increments of 0.01 or 0.001, would be computationally 
intensive but yield more precise effect estimates. As noted previously, because of 
randomization, we assumed that the transformed failure time , ( )i jU Ψ was 
independent of the randomization indicator, ,R i j , when Ψ  = 
*Ψ . This randomization 
assumption allowed us to evaluate whether a particular value of Ψ  equaled *Ψ  by 
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testing β=0 in the following proportional hazards model, where time was the potential 
failure time, using score tests: 
 
, ( ) 0 ,
( ) exp( * )
i jU i j
h h t RΨ = β  
 
These tests were similar to the standard ITT test of the effect of treatment because 
they preserved the original randomized group assignment.  The estimate Ψ of *Ψ , 
obtained when β=0, was the value of Ψ  for which the distribution of , ( )i jU Ψ  in the 
treated arm was approximately equal to the distribution , ( )i jU Ψ in the control arm.  
The test-based 95% confidence interval for Ψ  was { Ψ :Z( Ψ )<1.96}. 
 The strong version of the AFT model outlined above would only be relevant 
for studies in which all patients are followed until they experience the outcome. 
When using this version of the AFT model in the HIP PRO study, potential failure 
times could only be determined for individuals who experienced a hip fracture. To 
accommodate the balance of patients who were censored, we sought to modify the 
parameters of the AFT model above. There were two types of censoring in the 
current analysis, censoring by drop-out and censoring due to end of follow-up 
(administrative censoring). Initially, we considered only censoring by the planned 
end of study, where 440 (42%) individuals were administratively censored and 
experienced no hip fractures by the end of follow-up. To compute a potential time for 
these individuals, we defined the potential censoring time at end of follow-up, ,Ci j , as 
the time from randomization to the end of follow-up. Then, we replaced , ( )i jU Ψ , 
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which was unobserved for individuals who did not experience a hip fracture, with a 
function of , ( )i jU Ψ  and ,Ci j  that was observed for all individuals.
138 Note that 
because ,i jU  was independent of ,R i j , the function of , ( )i jU Ψ  and ,Ci j was also 
independent of ,R i j since the censoring time ,Ci j  was a baseline, pre-randomization 
covariate.  Let  
 
, ( )i j∆ Ψ = 1 if ,i jU  < ,C ( )i j Ψ , and 
, ( )i j∆ Ψ = 0 if ,i jU  ≥ ,C ( )i j Ψ , 
 
where ,C ( )i j Ψ = ,Ci j  if Ψ ≥0 and ,C ( )i j Ψ = ,Ci j * exp( )Ψ if Ψ <0. With this definition of 
,C ( )i j Ψ , we obtain that when a participant was censored ( ,i jT > ,Ci j ), ,i jU = ,C ( )i j Ψ , 
so that , ( )i j∆ Ψ was always observed.  In the Cox model defined above, instead of 
using ,{ , }i jT R to fit the model, we fit the model using , ,* ( ) min( , )i j i jT U CΨ = , the 
endpoint indicator , ( )i j∆ Ψ , and the treatment indicator ,R i j .
123-124, 138, 168 
In the HIP PRO study 564 (54%) study participants withdrew consent, died, or 
were lost to follow-up before experiencing a hip fracture or being administratively 
censored at the planned end of follow-up. While censoring due to administrative 
reasons can be viewed as being non-informative (because the date of study 
completion is a pre-randomization variable), censoring resulting from drop-out 
cannot be assumed to be completely at random. For such drop-out, post-treatment 
dependencies between censoring and outcome could arise. The methods described 
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earlier to deal with administrative censoring could not be used to deal with censoring 
by drop-out; an alternative strategy was required.   
We used inverse probability weights, which are similar to the Horvitz-
Thompson device in sampling theory, to account for the potential selection bias 
introduced by non-administrative censoring.169 Under this approach, we assumed 
that censoring due to drop-out was independent of the time to hip fracture, 
conditional on treatment status, age (< 80 years, ≥ 80 years), race (white/other), 
gender, hip fracture history (yes/no), marital status (never married, married, 
widowed, divorced/separated), osteoporosis history (yes/no), and cognitive status 
(based on the Short Blessed Test (SBT)126: normal/minimal impairment (SBT=0-8), 
moderate impairment (SBT=9-19), severe impairment (SBT≥20)). We specified a 
survival model, conditional on these covariates, to estimate a patient-specific weight 
iw  that equals the inverse of the probability that the participant remained 
uncensored until the occurrence of hip fracture or the administrative end of follow-
up, whichever came first. For individuals who dropped out of the study, the weights 
were set to zero, 0iw = . The individuals with non-zero weights created a pseudo-
population in which censoring due to drop-out was ignorable given the set of 
covariates, and the final g-estimation was applied to this pseudo-population. To 
account for the fact that we used estimates of the weights, we used robust variance 
estimates in our Cox model.170   
The g-estimation procedure estimated the survival time ratio, which described 
the association between exposure and survival using the accelerated failure time 
parameterization. Some have argued that such measures of change in survival are 
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often of greater public health interest than hazard ratios.124, 171-172 For the current 
analysis, however, we sought to compare the ITT hazard ratio with a hazard ratio 
obtained from g-estimation.  Therefore, we used a Weibull model (which can be 
expressed in either parameterization) to express the survival time ratio as a hazard 
ratio. We assumed that the underlying potential survival times followed a Weibull 
distribution and used the Weibull shape parameter κ  (estimated using maximum 
likelihood) to calculate the desired hazard ratio as follows: hazard ratio = exp( κ  * 
Ψ ). 
 We replicated the ITT analysis from the main HIP PRO study16 using a Cox 
model to compare hip fractures in hips that were randomly assigned to be protected 
with hip fractures in hips that were not protected.  In addition, we conducted a per-
protocol analysis in which we removed from the treatment arm any protected hips 
with an overall adherence less than 75%.  This is in slight contrast to the per-
protocol analysis in the main HIP PRO study, which used an overall adherence cut-
point of 80% to remove individuals from the analysis.  In an as-treated analysis, 
protected hips were re-classified an unexposed after any two week time period in 
which adherence was less than 75%. 
 
Results 
 
At baseline, the 1042 men and women comprising the study population were 
elderly, with a mean (standard deviation) age of 85.3 (7.4) years, and were mostly 
female and white. A majority was severely cognitively impaired, and approximately 
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one-third had a fall within 30 days prior to the baseline visit (Table 4.1).  The nursing 
homes participating in the study were approximately equally likely to be for-profit 
(49%) and not-for-profit, and most of the nursing homes allowed residents to wear 
hip protectors some or all of the time at night (83%).  Overall adherence for 
protected hips was 74%. 
A total of 564 (54%) study participants dropped out of the study before 
experiencing a hip fracture and before the administrative end of the study.  
Treatment assignment did not affect the likelihood of drop-out.  Drop-out was 18% 
higher for participants < 80 years when compared to participants ≥ 80 years, and 
was 23% higher for males when compared to females (Table 4.2).  Conversely, the 
drop-out was 20% lower for participants with a hip fracture history when compared to 
participants with no hip fracture history, and 25% lower for participants with severe 
cognitive impairment when compared to participants with no/mild cognitive 
impairment.  For the 478 patients with non-zero drop-out weights, the mean 
(standard deviation) was 2.18 (0.89) and the range was (1.01, 11.33). 
 In table 4.3 we present the replication of the ITT analysis, as well as four 
other estimates of the effect of hip protectors. Replicating the ITT analysis using Cox 
regression yielded a 24% increased hazard of hip fractures, when comparing 
protected hips to unprotected hips. Controlling for clustering within nursing homes 
did not meaningfully change the ITT results, with only a light loss in precision 
(hazard ratio=1.24 (95% CI: 0.64, 2.37)). For the per-protocol analysis, where we 
removed from the analysis any protected hips with an overall adherence less than 
75%, the hazard of hip fractures was 40% higher in protected hips when compared 
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to unprotected hips.  The as-treated analysis suggested a 16% increased hazard of 
hip fractures when compared protected hips to unprotected hips.  In contrast to the 
ITT, per-protocol, and as-treated analyses, which suggested a harmful effect of hip 
protectors, the analysis using structural nested models suggested a protective effect 
of hip protectors.  When we assumed that drop-out was completely at random, we 
obtained a hazard ratio of 0.53 (95% CI: 0.10, 2.74) when using a structural nested 
model; the results did not meaningfully change when we assumed that drop-out was 
random, conditional on the set of baseline covariates. 
 In Figures 4.1 and 4.2 we plotted a set of β’s by the test statistic.  These 
figures served to demonstrate the association between the potential treatment-free 
survival time and treatment assignment for many choices of β.  Note that the 
function of (β) was not smooth in both figures because the test statistic jumped 
suddenly as β was varied.  β=0 represented the null hypothesis of no treatment 
effect, while the β with an associated test statistic that was closest to zero was our 
estimate of the treatment effect.  In Figure 4.1, where we assumed that censoring 
due to drop-out was completely at random, this minimum occurred at -0.91, yielding 
a time ratio ( e−β ) of 2.48.  In Figure 4.2 we assumed that drop-out was random 
conditional on a set of baseline covariates, and obtained a time ratio of 2.41 (e-(-0.88)). 
 We assessed modification of the effect of hip protectors by gender and age.  
The effect of hip protectors was similar for the 821 females in the HIP PRO study 
(hazard ratio = 0.54 (95% CI: 0.07, 4.29)) and the 221 males (hazard ratio = 0.56 
(95% CI: 0.04, 8.10)).  There was a suggestion of stronger but very imprecise 
protective effect of hip protectors in participants less than 80 years of age (hazard 
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ratio = 0.31 (95% CI: 0.01,12.53)), when compared to participants greater than 80 
years of age (hazard ratio = 0.60 (95% CI: 0.08, 4.08)). 
 
Discussion 
 
 Using a structural nested model, we found that constant exposure to hip 
protectors expanded the time to a hip fracture by approximately 2.5; this 
corresponds to an approximate 50% reduction in the hazard of hip fractures. In 
contrast to the ITT effect estimate, the adherence corrected hazard ratio 
demonstrated a protective but less precise effect of hip protectors. 
To estimate an adherence-corrected effect of hip protectors on survival time 
we made several assumptions. First, we assumed that the structural accelerated 
failure time model was correctly specified and it captured the biological treatment 
action of hip protectors on hip fractures. Intrinsic to this assumption was that 
adherence and hip fractures had been measured without error. Second, we 
assumed that there was no modification of the treatment effect across time or with 
respect to patient characteristics. This non-interaction assumption obviated the need 
to check for time-by-treatment and time-by-covariate interactions.129 However, we 
also fit two-parameter structural nested models to allow for modification by age, and 
gender. Our results did not vary greatly by these sub-groups, suggesting that the 
one-parameter structural nested model was reasonable. Third, we assumed that the 
potential treatment-free failure time ,Ui j for hip ,i j was unaffected by the treatment 
assignment or the potential survival time of other individuals.  Finally, we assumed 
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that the exclusion restriction holds, such that there is no effect of treatment 
assignment other than through its impact on received treatment.     
 The g-estimation approach used in this analysis does have certain potential 
weaknesses. One potential weakness is that the extra censoring introduced at 
certain levels of Ψ  by accounting for end of follow-up results in estimates of lowered 
precision.  This artificial censoring is necessary to avoid selection bias but it can 
discard potentially useful failure-time information.138  When the number of outcomes 
is small prior to re-censoring, as was true with the HIP PRO study, the final effect 
estimate obtained from g-estimation is likely to be imprecise. Another potential 
weakness of the g-estimation approach is that it assumes that drop-out is non-
informative. Except in studies where all participants are followed for an event that 
can be assessed by external data sources (e.g., total mortality), accounting for 
censoring due to drop-out will be necessary. In HIP PRO, 54% of study participants 
dropped out of the study. For the main adherence corrected effect estimate, we 
accounted for this substantial drop-out by using weights and assumed that drop-out 
was random conditional on a set of measured baseline covariates that comprised 
the weights. In addition, we also obtained an adherence corrected effect estimate 
where we assumed that drop-out was completely at random. The similarity of the 
results with these two approaches suggest that drop-out in HIP PRO may be non-
informative, unless there exists an unmeasured covariate that was strongly 
predictive of drop-out but which we did not include in our weights. 
 In a previous analysis, we employed inverse probability of censoring weights 
(IPCWs) to correct for non-adherence in the HIP PRO study and obtained a hazard 
 
 
109 
 
ratio of 0.55 (95% CI: 0.13, 2.40).  The IPCW approach considered participants as 
dependently censored when they wore hip protectors in fewer than 75% of 
adherence visits, in any two-week period.  This dependent censoring was then 
adjusted, using information on time-invariant and time-varying covariates that were 
thought to be common causes of randomization and non-adherence.132  An 
advantage of using the IPCW approach to non-adherence correction is that no 
participant information is needed after the date of non-adherence. One 
disadvantage, however, is that the IPCW approach assumes that information on all 
important prognostic factors of non-adherence and hip fractures has been accurately 
measured and modeled.  The structural nested modeling approach used in the 
current analysis makes no such assumption.  If we assume that censoring from 
drop-out is non-informative, then this approach relies only upon the relationship 
between pre-randomization variables and potential outcomes. 
 As-treated and per-protocol analyses have often been employed in 
randomized studies with poor adherence (due to ease of implementation), 
sometimes with the mistaken belief that these analyses resolve the problem inherent 
in an ITT analysis. While these analyses do guarantee a correct classification of 
exposure, they do not guarantee comparability (or, more precisely, 
exchangeability)170 of the groups defined by this exposure. With per-protocol 
analysis only those individuals who adhere to their assigned treatment are included 
in the analysis. The as-treated analysis uses all of the data but compares individuals 
who were randomized to treatment and complied, with a mixed group of compliers 
and non-compliers who received no treatment.127, 135-136 When compliers and non-
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compliers have a different prognosis at baseline (i.e., when outcome dependent non-
adherence is present), both the as-treated analysis and the per-protocol analysis will 
give biased estimates of the effect of treatment. In contrast, the g-estimation 
approach, as noted previously, relies on the original randomization and is valid even 
when there is outcome dependent non-adherence, as long as the underlying 
structural model is correct.129, 160  
 The assumptions of structural nested models were similar to those used in 
the instrumental variable (IV) approach for non-adherence correction, where 
randomization was considered the instrument, randomization was associated with 
treatment actually received, but randomization was only associated with the 
outcome (e.g., hip fractures) through its association with treatment received (i.e., 
there were no common causes of randomization and the outcome).121 We attempted 
to implement an alternative IV approach to correct for non-adherence in the HIP 
PRO study, by comparing rates between treatment arms among “would-be 
compliers,” those who would have worn hip protectors if assigned to wear them and 
those who would not have worn the hip protectors if not assigned to wear them. This 
method requires borrowing information from a subset of patients (“always takers” or 
“never takers”) in the alternate treatment arm to inform the rates in the “would-be 
compliers.”134, 139, 145  In the HIP PRO study, the number of “never takers” could not 
be calculated in the no-treatment arm, and so the rate for those who would have 
worn the hip protectors if assigned to wear them could not be calculated. While an IV 
effect estimate could not be calculated for the HIP PRO study, this approach would 
be relevant for non-adherence correction in studies where accounting for follow-up 
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time is not relevant.  One advantage of structural nested models, when compared to 
the simple IV approach outlined above, is that structural nested models account for 
the timing of outcomes as well as non-adherence.124  
To correct for non-adherence in the HIP PRO study, we have employed 
several competing methods to estimate adherence-corrected treatment effects. 
Results from both IPCWs and the structural nested models in the current analysis 
suggest that hip protectors may be protective. As with any modeling strategies, 
these methods rely on additional assumptions beyond those needed for an ITT 
analysis. Nevertheless, the treatment effects revealed by these analyses account for 
post-randomization non-adherence and should serve to supplement the findings 
from an ITT analysis. 
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Tables and Figures 
 
Table 4.1.  Selected Baseline Characteristics of 1042 Men and Women Randomized 
to Wear Hip Protectors on Either the Left Hip or the Right Hip in the Hip Impact 
Protection Project (HIP PRO). 
 
Characteristic 
Nursing Home Residents 
(N=1042)b 
Women 821 (78.8) 
Whitea 895 (85.9) 
Age, Mean (SD), year 85.3 (7.4) 
History of osteoporosisa 202 (19.4) 
History of fall in last 30 daysa 301 (29.2) 
Marital statusa  
  Never 193 (18.5) 
  Married 153 (14.7) 
  Widowed 631 (60.6) 
  Divorced/Separated 65 (6.2) 
Cognitive statusa,c  
  Normal / Mild impairment 151 (14.5) 
  Moderate impairment 147 (14.1) 
  Severe impairment 744 (71.4) 
aMissing data (<3% of total residents) replaced with mode of distribution. 
bRepresents total N(%), unless otherwise noted 
cCognitive status categories based on Short Blessed Test (SBT): normal / minimal 
impairment  (SBT = 0 – 8), moderate impairment (SBT = 9 – 19), severe impairment 
(SBT ≥ 20). 
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Table 4.2. Hazard ratios and 95% confidence intervals for covariates used to fit a 
survival model for the probability of drop-out. 
Variablea Category 
Hazard 
Ratio 
95% Confidence 
Interval 
Treated Hip  0.99 0.88, 1.12 
Age > 80 Years  1.18 1.02, 1.38 
Non-white Race  1.07 0.91, 1.28 
Male Gender  1.23 1.05, 1.43 
Hip Fracture History  0.79 0.63, 1.00 
Osteoporosis History  0.90 0.77, 1.05 
Marital Status Single 1.00  
 Married  0.95 0.71, 1.25 
 Widowed 0.93 0.70, 1.25 
 Divorced 1.20 0.92, 1.52 
Cognitive Status No / Mild Imp. 1.00  
 Moderate Imp. 0.98 0.80, 1.22 
 Severe Imp. 0.75 0.64, 0.89 
a All variables were measured at baseline. 
b Cognitive status categories based on Short Blessed Test (SBT): normal / minimal 
impairment (SBT = 0 – 8), moderate impairment (SBT = 9 – 19), severe impairment 
(SBT ≥ 20).
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Table 4.3. Hazard ratios and 95% confidence intervals for the effect of hip protectors 
on time to hip fractures among 1042 nursing home residents. 
Analysis Hazard ratio 95% Confidence interval 
Intention-to-treat 
Per-protocola 
1.24 
1.40 
0.65, 2.34 
0.69, 2.85 
As-treatedb 1.16 0.59, 2.30 
Structural nested model:  
drop-out completely at 
randomc 
0.53 0.10, 2.74 
Structural nested model: 
drop-out not at randomc,d 
0.46 0.07, 2.84 
a Hips with overall adherence < 75% were removed from the analysis (note that 
unprotected hips were 100% adherent). 
b Exposure status was time-varying, and, for exposed hips, was re-defined as 
unexposed after any two week time period in which adherence was less than 75%. 
c Assumed that the underlying potential survival times followed a Weibull distribution.  
d Assumed that drop-out was random conditional on the following baseline 
covariates: treatment status, age, race, gender, hip fracture history, marital status, 
osteoporosis history, and cognitive status. 
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Figure 4.1. Plot of β by the Wald Chi-square test, assuming that censoring due to 
drop-out was completely at random. 
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Figure 4.2. Plot of β by the Wald Chi-square test, assuming that censoring due to 
drop-out was ignorable given a set of baseline covariates. 
 
 
 
                                                 Chapter 5 
CONCLUSION 
 
FUTURE METHODOLOGICAL DIRECTIONS 
 
We have seen that, in the presence of non-adherence, there are several valid 
alternative methods to estimate efficacy in randomized studies.  Despite the 
existence of these methods, current regulatory practice still largely relies on the ITT 
analysis.  There appear to be two main reasons for this preference.  First, the ITT 
analysis simplifies decision-making.  There is no need to consider post hoc modeling 
and analyses to account for non-adherence.  In contrast to complicated and, 
perhaps, subjective model-based analyses, a simple ITT analysis with easily 
understood conclusions is preferred.  However, an ITT analysis may not answer the 
main question of interest when non-adherence is substantial (i.e., does the receipt of 
treatment have an effect on the outcome).  We contend that if non-adherence is 
present in more than a trivial proportion of participants, we must adopt more 
elaborate models to estimate efficacy.  In this situation, a simple ITT analysis will not 
be adequate.  As long as the assumptions are clearly defined and understood, the 
use of more complex analyses should not be abandoned altogether.  A second 
reason for the preference of ITT analysis is the belief that any analysis that is not 
based on the original randomization is biased.135  This is not always true, as 
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demonstrated with the analysis using inverse probability-of-censoring weights in 
Chapter 3. 
If we accept the need for alternatives to the ITT analysis in the presence of 
non-adherence, as we have done, there still remains a need to better understand the 
strengths and weaknesses of each approach.  Instrumental variable (IV) analysis 
and analyses using structural nested models (SNMs) do not require information on 
the common causes of non-adherence and the outcome, but do require that 
individuals are followed until the planned end of the study.  Analyses using inverse 
probability of censoring weights (IPCWs), in contrast, require no follow-up 
information after the study participant first becomes non-adherent, but do require 
that all important concomitants of non-adherence and the outcome are measured.  
Thus, we do have good understanding of when a particular method to correct for 
non-adherence may be most applicable.  In many situations more than one method 
may be appropriate.  When this is true and the analyses reveal similar results we 
may be more confident in the findings because each of the methods rely on different 
approaches and assumptions. 
Still, questions remain.  For example, it appears that the simple IV approach 
that we attempted to use is guaranteed to result in an adherence-corrected effect 
estimate that is stronger than the ITT effect estimate and which remains on the 
same side of the null.  Is it reasonable that this is always true?  We have seen with 
the IPCW and SNM analyses that non-adherence can result in a biased estimate 
that goes through the null.  Another question that remains is ‘to which study 
population does the effect estimate apply?’  The target population of an ITT or IPCW 
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analysis is the total study population.  In contrast, the target population of the IV 
approach is the ‘would-be compliers’ (i.e., those who would comply if assigned either 
treatment).  For the SNM analysis, the effect estimate appears to be applicable to 
the actual complies, which, in certain circumstances (e.g., a randomized control 
trial), will be the same as the ‘would-be compliers’ because of randomization.  We 
explore the target populations of an ITT analysis, an IV analysis, and an SNM 
analysis, using indirect evidence under a simulation exercise.  The findings from the 
simulation exercise are presented in Appendix 4. 
 
IMPROVING NON-ADHERENCE IN FUTURE HIP PROTECTOR STUDIES 
 
Non-adherence is a multi-factorial problem which is influenced by the study 
setting, the treatment regimen, the characteristics of the disease, and patient 
characteristics, some of which are stable and others that are time-varying.  With the 
hip protector intervention, we have seen that adherence may be different in 
institutional settings versus community settings, that the appearance and design of 
the hip protector impacts the use of the intervention, and that a patient’s gender, 
age, cognitive status, continence, and other factors play a role in adherence.  The 
complexity in the factors influencing adherence can usually be ignored when non-
adherence is low.  In hip protector studies, however, non-adherence has been 
pervasive and high, and, so, cannot be ignored.  Consequently, the goal of this 
dissertation has been to implement methods to account for non-adherence in one 
particular randomized study of hip protector, the HIP PRO study.  These methods 
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are important because they provide alternative tools for the epidemiologist to 
estimate effects, even in situations were non-adherence is unavoidable.  However, 
the goal of future hip protector studies should not be simply to account for non-
adherence, but also to improve adherence. 
With the exception of the Meyer et al118 and Kiel et al16 studies, pervious 
efforts at improving adherence have often been limited to one of the following 
strategies: (1) providing pamphlets or videos that discuss the risk of hip fractures 
and the benefits of hip protectors, (2) using nursing or study staff to measure and 
encourage adherence, (3) improving the design of the hip protectors to decrease 
discomfort and improve convenience.  In contrast, Meyer et al118 used a more 
holistic approach to improve adherence, using social learning theory.173-174  They 
used educational sessions to identify a target population that was interested in 
learning about the risk of hip protectors, believed that hip protectors could reduce 
the risk of fractures, and felt susceptible to hip fractures.  After enrollment in the 
study, caregivers used verbal persuasion and encouragement to improve self-
efficacy, and thus, adherence.  Other competing theories, such as contingency 
contracting175, which gives patients greater control over their own medical care, also 
provide a more comprehensive approach to improving adherence.  The attraction of 
these alternate approaches is that they have a multi-factorial approach that 
incorporates information on how individuals conceptualize, cope, and appraise their 
illness state and address the psychological processes underlying a patient’s non-
adherence.176  Unfortunately, such approaches necessarily restrict the population 
and limit the ability to generalize study findings to the broader elderly population.  
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For example, cognitive impaired individuals would be excluded under both 
approaches above.   
Some would argue that it would be inappropriate to exclude individuals with 
dementia from hip protector studies.  As evidenced by the characteristics of the HIP 
PRO study population, many individuals in long-term care settings will be cognitively 
impaired.  If these individuals are included in efficacy trials of hip protectors, the 
main driver of adherence will be the caretakers.  As with study participants, the 
strategies to improve adherence through caretakers include knowledge about the 
risk and consequences of hip fractures for patients.  This knowledge can be 
provided by trained personnel, videos, pamphlets, or any combination of these 
strategies; group discussions with peers can fill in gaps of knowledge and provide 
the social support that fosters an environment in which encouragement of adherence 
becomes an important institutional goal.  The purpose of such training is to 
overcome the educational, emotional, and behavioral barriers in caretakers that may 
hinder or limit adherence in their patients.  Factors that can be especially important 
in the interaction between caretakers and patients with cognitive impairment include 
practitioner warmth and concern, sensitivity to patient’s non-verbal behavior, and 
using appropriate non-verbal cues to respond to patients.177  Caretakers should be 
encouraged to practice the skills needed to aid in improving adherence.  Improving 
these skills with cognitively impaired patients will result in improved interaction with 
all patients. 
In the past, the biomedical framework has viewed non-adherence as resulting 
from aberrant behavior on the part of the patient who refuses and disobeys the 
 
 
122 
 
prescription of treatment regimens.  This model focused on the influence of patient 
characteristics on adherence, and did not address factors and cognitive processes 
that can also influence adherence.  The focus had been on identifying groups at risk 
of non-adherence, but has had limited influence in improving adherence.  The 
alternative theoretical frameworks outlined above have strengths and weaknesses 
and may not be appropriate in every situation.  In the context of future hip protector 
studies, it is the investigators responsibility to decide which approach, or 
combination of approaches, might best help to improve adherence in the particular 
study population that she is studying.  Such thoughtful approaches should help to 
improve adherence.   
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Appendix I 
Search Criteria for Systematic Review 
 
PubMed Search statement: 
 
(hip fracture* OR (femor* AND neck[tw]  AND fracture*)) OR "hip fractures"[MeSH 
Terms]  AND ("protective devices"[MeSH Terms] OR protective device* OR protective 
cloth* OR hip protector* OR hip pad*) AND (randomized controlled trial[pt] OR 
controlled clinical trial[pt] OR "randomized controlled trials"[MeSH Terms] OR "random 
allocation"[MeSH Terms] OR "double-blind method"[MeSH Terms] OR "single-blind 
method"[MeSH Terms] OR (random* AND control* AND trial*)) AND "aged"[MeSH 
Terms]  
 
CINAHL Search Statement: 
 
( (((MH "Hip Protectors")) or (MH "Protective Clothing") or (protective cloth*) or 
(protective device*) or (hip pad*)) and ((MH "Hip Fractures") or (hip fracture*) or (femor* 
and neck and fracture*)) ) and ((MH "Clinical Trials+") or (random* and control* and 
trial*)) and (MH "Aged+") 
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Cochrane Search: 
 
Use Cochrane Phase 1 search to limit results as closely as possible to RCTs. Rationale: 
PubMed RCT publication type has been in use since 1991. The earliest pertinent article 
retrieved using the broader All Phases search was from 1993. Since this is a relatively 
recent topic, we do not need all the possible text words related to RCTs in the All 
Phases search which aid in finding articles older than 1991 that were not well indexed to 
RCTs. Phase 1 results provide an adequate balance of precision and retrieval. 
 
Cochrane Clinical Trials Search Statement 
#1 MeSH descriptor Hip Fractures explode all trees 669 
#2 MeSH descriptor Protective Devices explode all trees 1168 
#3 (hip near fracture* OR femor* near neck near fracture*) 1304 
#4 
(protective near device* OR protective near cloth* OR hip near protector* 
OR hip near pad*) 
549 
#5 (( #1 OR #3 ) AND ( #2 OR #4 )) 43 
 
ISI Web of Science Statement:  
 
(TS=(hip fracture* OR (femor* AND neck[tw] AND fracture*)) AND (protective device* 
OR protective cloth* OR hip protector* OR hip pad*)) 
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DocType=Meeting Abstract OR Meeting Summary OR Meeting-Abstract; Language=All 
languages; Databases=SCI-EXPANDED, SSCI, A&HCI; Timespan=1955-2009) 
 
EMBASE Search 
Use the search strategy used for the PubMed data base, keeping only references that 
were not identified in the PubMed data base. 
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Appendix 2 
Description of Selected Publications Identified in a Systematic 
Review of Randomized Hip Protector Studies 
 
 Lauritzen and colleagues88 conducted the first randomized study of hip 
protectors in Denmark, using a hip protector design that would later become standard 
for the SafeHip hip protector.  Within one nursing home 10 wards (247 participants) 
were randomized as hip protector wards, while 18 wards (418 participants) were 
provided no protectors.  During eleven months of follow-up 8 hip fractures occurred in 
the hip-protector group and 33 hip fractures occurred in the unprotected group, yielding 
a rate ratio (95% CI) of 0.44 (0.21, 0.94).  Adherence was evaluated only in a fall sub-
study in two wards from the treatment arm and it was noted that hip protectors were 
being used only during 14/45 (21%) of registered falls. 
 As the first study of hip protectors with a precise and beneficial effect of hip 
protectors, the study of Lauritzen et. al. was influential in prompting additional interest in 
the use of hip protectors to prevent hip fractures.  Unfortunately, the study was of poor 
quality, with questionable design issues, and suffered from inappropriate analyses.  No 
data was provided to demonstrate balance of ward characteristics among the 
randomization arms, or to demonstrate the balance of patient demographic 
characteristics and medical history.  Also, during the course of the study, patients who 
dropped out of the study were replaced from a waiting list.  In the presence of non-
random drop-out such post-randomization replacement could negate some or all of the 
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benefits of randomization.  Finally, in the analysis, the study authors did not adjust for 
clustering within wards of the nursing home.  Failure to account for the clustering would 
have resulted in overly precise effect estimates. 
 Ekman et al110 conducted the next randomized study of hip protectors using 
protectors (JOFA AB, Malong, Sweden) that were similar to those employed by 
Lauritzen, where one nursing home (302 residents) was randomized to the hip protector 
arm and the remaining three nursing homes (442 residents) were assigned to the no hip 
protector arm.  After 11 months of follow-up, 4 hip fractures occurred in the treatment 
arm and 17 in the control arm.  A relative risk estimate of 0.33 (95% C.I.: 0.11, 1,00) 
supported the earlier findings of Lauritzen et al, and suggested that hip protectors may 
prove a strong protective effect.  The overall “average” adherence was better at 44%; 
however, adherence measurement was not clearly defined.  The major reasons for non-
adherence included skin irritation and being bed-ridden.  As with the Lauritzen trial, 
there was a lack of adjustment in the analysis for cluster randomization.  Because the 
study by Ekman et al was a brief report, potentially important information on the timing 
of hip fractures and drop-out was not reported. 
 Another brief report, in a letter to the editor by Jantti et al116, presented results in 
1998 for seventy-two residents, residing in a municipal nursing home in Finland, who 
were equally randomized to wear hip protectors and not to wear hip protectors.  The hip 
protector used in the study was designed by one of the authors and employed a 
polyethylene foam padding that was also used in knee protectors by hockey players.  
Participants were followed for one year and during this time one hip fracture occurred in 
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a protected hip, while seven hip fractures occurred in the control arm (RR (95% CI): 
0.14 (0.02, 1.10)).  The authors used an unusual definition of adherence, noting that of 
the 19 participants who were still living in the nursing home at the end of follow-up, 13 
(68.4%) were still wearing the hip protectors.  Also, the method by which adherence 
was evaluated was not clear.  For those who continued to wear hip protectors, the 
reasons for adherence included the fact that the protectors were warm, the protectors 
increased the feeling of safety, and diminished the fear of falling.  The authors failed to 
account for the background rate of hip fractures and provided insufficient power to 
determine a meaningful estimate of the effect of treatment. 
 A pilot study by Villar and colleagues87 in the United Kindom was designed to 
evaluate adherence of nursing home residents to the wearing of hip protectors.  The 
study randomized 101 rest home patients to wear hip protectors with an outer shield of 
polypropylene and inner plastozote lining; 40 rest home residents were randomized to 
the no treatment arm.  During twelve weeks of follow-up no hip fractures occurred in 
either arm of the study.  Adherence was monitored by randomly timed visits every 14 
days.  At the end of the study only 27 residents (27%) wore the hip protectors for the full 
12 weeks.  The reasons given for non-adherence included discomfort and poor fit; other 
reasons included physical difficulty, changed mind, illness, and forgetfulness.  Although 
the authors clearly state that the purpose of the study was to evaluate adherence and 
not to demonstrate efficacy, the study nevertheless demonstrates that a study of short 
duration and small sample size would be unable to evaluate the efficacy of hip 
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protectors.  The risk of hip protectors, even in an institutionalized setting, is small during 
such a short follow-up time. 
 One of the largest randomized studies of hip protectors was undertaken by 
Kannus and colleagues89 in 22 community-based health centers in Finland.  
Randomization occurred at the facility level in a 1:2 ratio to either a hip protector group 
or to a control group.  Although the number of facilities in each treatment arm was not 
clear, 653 individuals were designated to wear the hip protectors and 1148 were 
assigned to the control group.  The investigators used the KPH hip protector, one of the 
first hip protectors to be worn inside pockets of an undergarment.  In the treatment 
group there were 13 hip fractures, while in the control arm there were 67 hip fractures; 
the relative hazard (95% C.I.) was 0.4 (0.2, 0.8).  Adherence, defined as the number of 
days the hip protector was worn as a percentage of all follow-up days, was 48%.  In the 
treatment arm 31% of participants completely refused to wear the hip protectors after 
randomization.  As with previous studies, there were only minor adverse events 
associated with wearing the hip protectors, including skin irritation, abrasions, and 
swelling of the legs.  During follow-up four subjects in the treatment arm experienced a 
hip fracture, despite wearing the hip protectors at the time of the fall.  Because of 
variable patient demographics and medical history, as well as variation in the 
characteristic of the fall, hip protectors were not always protective, even when worn 
correctly.  In the analysis, the authors failed to account for clustering within facilities; 
nevertheless, the results from the study contributed to mounting evidence that hip 
protectors were strongly protective against hip fractures. 
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 Birge et al113 presented results from a randomized study of hp protectors in an 
abstract.  Randomization occurred at the nursing home level in 18 nursing homes (317 
residents).  The number of nursing homes and the number of residents in each 
treatment arm was not provided.  Four hip fractures occurred in protected hips and six 
hip fractures occurred in unprotected hips.  Because follow-up time was provided only 
for protected hips, a measure of effect could not be estimated.  Overall adherence in the 
study was 63%.  However, it was not clear how adherence was defined and measured.  
The failure to include important randomization information in the abstract limited the 
contribution of the study to the literature. 
 The first study of hip protectors in which randomization occurred at the individual 
level was undertaken by Cameron and colleagues103 in Australia.  Inclusion criteria 
limited the study population to women aged 75 years and older who were at high risk of 
falling, and lived in hostels or nursing homes.  Eighty-six participants were randomized 
to wear the SafeHip hip protector and eighty-eight participants were randomized to the 
control group.  During eighteen months of follow-up eight hip fractures occurred in the 
intervention group and seven hip fractures occurred in the control group; the hazard 
ratio (95% CI) was 1.46 (0.53, 4.51).  A unique feature of the study was that an 
adherence nurse encouraged participants and facility staff to increase the use of hip 
protectors in the treated group; the nurse evaluated adherence at two weeks, and at 2, 
10, and 18 months.  Adherence, defined as the use of hip protectors for at least half of 
the day, was 70% during the first two months of the study, but declined to approximately 
50% by the end of the study.  The small study size resulted in an imprecise effect 
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estimate.  Nevertheless, this was the first study to suggest that hip protectors may not 
be as beneficial as previously reported.  Randomization at the individual level may have 
been problematic for institutionalized participants because staff members, with limited 
time for non-care activities, may have not been able to implement distinct treatment 
plans for individuals in the two unique treatment groups. 
 Harada et al91 conducted another small randomized study in elderly female 
residents in Japanese nursing homes, where the unit of randomization was the 
individual.  There were 164 participants who were not wheel-chair bound and had the 
ability to stand unaided.  Of the 164 eligible nursing home residents, 88 were 
randomized to wear “shell-shaped, polypropylene” hip protectors and 76 were 
randomized to not wear the protectors.  The average follow-up time was 360 (S.D. 255) 
days for the treatment group and 397 (S.D. 244) days for the control group.  During this 
time one hip fracture occurred in protected hips and eight hip fractures occurred in the 
untreated group.  Despite a successful randomization which adequately balanced 
patient characteristics in the randomization arms, the investigators conducted an 
adjusted Cox regression analysis, controlling for patient age, body weight, height, grip 
strength, tricep skin-fold thickness, and number of falls per subjected.  The adjusted 
hazard ratio for the effect of hip protectors was 0.08 (0.01, 0.75).  Adherence was 
evaluated daily by care staff and was measured in three categories: (1) complete 24 
hour wearing, (2) incomplete wearing, and (3) not wearing the protector at all.  The 
investigators reported a surprisingly high rate of complete wearing of 70% at the end of 
the study and 17% incomplete wearing.  The high adherence in this study relative to 
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previous studies of hip fractures may be a result of cultural factors, patient case-mix, 
and, as suggested by the authors, highly motivated staff members in the nursing 
homes. 
 One study by Birks and colleagues95 was conducted among community 
dwelling individuals who had a history of a previous hip fracture, presumably because 
these individuals were at high risk of a second hip fracture and would be highly 
motivated to prevent a second hip fracture.  Participants were recruited by television 
and newspaper advertisements, as well as from orthopedic wards, when individuals 
were to be discharged back home.  Eligible participants were 70 years or older, were 
not bed or chair-bound, and had a single previous hip fracture.  The 182 individuals 
randomized to the treatment arm were issued 3 SafeHip hip protectors, while 184 
controls received no hip protectors.  The main outcome was a second hip fracture, 
which was ascertained by contacting the general practitioner for each study participant.  
Six hip fractures occurred in the treatment group and two hip fractures occurred in the 
control group.  Logistic regression analysis yielded an unadjusted odds ratio (95% C.I>) 
of 3.10 (0.62, 5.58).  Self-reported adherence indicated that 60% of individuals in the 
treatment group still occasionally wore the hip protectors at the end of the study, but 
only 34% always wore the garments.  Self-reported adherence tends to be higher than 
adherence evaluated by external monitors.  As a result, it may be that the true 
adherence is even lower than suggested by self-report.  Details for outcome 
ascertainment were sparse (e.g., there was no information provided about the response 
rate for general practitioners who were contacted about the occurrence of a second hip 
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fracture); if the response rate was differential for the two treatment arms then the study 
results would be biased.  Also, it is not clear whether control patients were prohibited 
from wearing hip protectors.  If there was important hip protector use in the control 
group then the estimate of the effect of hip fractures would also be biased.  
 Another study which evaluated the efficacy of community dwelling individuals 
occurred in Australia.  Cameron et al96 randomized cognitively intact women who were 
74 years of age or older, lived in their own homes, and were at a high risk for falls, to 
receive SafeHip hip protectors and contact with an adherence nurse, or to receive no 
treatment.  Out of a total of 600 eligible women, 302 were randomized to the treatment 
arm and 298 were randomized to the control arm. Planned follow-up was for two years, 
and, after randomization, residents were allowed to continue wearing hip protectors 
even if they no longer resided in their own homes.  There were twenty-one hip fractures 
in the treatment arm and twenty-two hip fractures in the controls.  The intention-to-treat 
estimate of the relative risk (95% CI) was 0.93 (0.51, 1.69), indicating no effect of 
treatment.  As in the Birks 2003 study, the outcome was ascertained by self report, with 
follow-up of radiography reports and hospital records.  Adherence was encouraged by 
nurses during in-home visits and by telephone calls.  Self-reported adherence was 
defined as the amount of time that hip protectors were worn during the day.  During the 
first year of follow-up 57% of participants reported wearing the hip protectors at least 
half of the day; by 18 and 24 months, however, adherence had fallen to 50% and 42%, 
respectively.  As in the Birks et al study, the attempt to determine the effectiveness of 
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hip protectors in a community setting was admirable.  However, inadequate exposure 
and outcome ascertainment make the estimate of efficacy difficult to interpret. 
 A study by Meyer and colleagues in Germany118 used social learning theory to 
design a randomized study in which individuals in the treatment arm (as well as the staff 
of the nursing homes) received a structured education program, in addition to the 
SafeHip protector.  In the control arm participants were offered a short introduction to 
hip protectors and they then had the option to also wear hip protectors.  Randomization 
was at the level of the nursing home, with 25 nursing homes assigned to the 
intervention arm and 24 nursing homes to the control arm.  The 459 participants in the 
intervention arm and 483 residents in the control arm had a high risk for falling, were 70 
years of age or older, were not bed-ridden, and had lived in a nursing home for more 
than three months at baseline.  During eighteen months of planned follow-up, 21 hip 
fractures occurred in the intervention group and 42 hip fractures occurred in the control 
group – the relative risk (95% CI) of hip fractures was 0.57 (0.19, 0.92), when 
comparing protected to unprotected hips.  The authors reported only adherence during 
falls and noted that participants in the treatment arm were wearing the hip protector 
during 54% of falls; in the control group, hip protectors were worn in 8% of falls.  
Because individuals in the control group were not prohibited from wearing hip 
protectors, 40/483 (8%) of the participants in the control group used a hip protector 
during the study.  The unusual study design, where control participants were also 
allowed to wear hip protectors, probably attenuated the true effect of hip protectors in 
this study.  
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 A large, well-designed study was undertaken by van Schoor and colleagues107 
in the Netherlands, where residents of apartment houses for the elderly and residents of 
nursing homes were randomly assigned to receive SafeHip hip protectors or not.  In 
both the intervention arm and the control arm, participants and nurses were provided 
education about the risk for hip fractures among institutionalized individuals and about 
the causes and consequences of hip fractures.  The study population was restricted to 
individuals aged 70 years of age or older who had a high risk for falling, but who were 
mobile and did not have a history of bilateral hip fractures.  Of 561 individuals who met 
the eligibility criteria, 276 were randomized to the intervention arm and 285 were 
assigned to the control arm.  Total follow-up in the intervention arm was 357 person-
years, during which 18 hip fractures occurred.  In the control arm 20 hip fractures 
occurred during a total follow-up of 398 person-years.  The hazard ratio (95% CI) for the 
effect of hip protectors was 1.05 (0.55, 2.03).  Adherence was assessed during 
unannounced visits by a research assistant at 1, 6, and 12 months after inclusion in the 
study (this was the first study in which adherence was evaluated by unannounced 
visits).  Newsletters were sent to the nurses of the elderly care homes and nursing 
homes to encourage and emphasize the importance of adherence.  Despite these 
efforts, overall adherence in the study was similar to other studies.  Adherence was 
61% at 1 month, 45% at six months, and 37% at twelve months.  In addition to the 
intention to treat analysis, the authors also presented results from a per-protocol 
analysis where, in the treatment arm, they kept only participants who were adherent 
during all three unannounced adherence visits.  The per-protocol hazard ratio (95% CI) 
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was 0.77 (0.25, 2.38).  When adherence is low investigators often rely on the per-
protocol analysis to estimate the effect of treatment in only adherent patients.  However, 
because the per-protocol analysis relies on post-randomization decisions to keep 
patients in the intervention arm, the results of such an analysis can be severely biased. 
 Birks et al112 conducted another randomized study of hip protectors among 
women living in the community in the United Kingdom.  Volunteers were recruited from 
the age-sex registers of general practitioners and through media advertisements.  
Volunteers were eligible for the study if they were female, older than 70 years of age, at 
high risk for a hip fracture, living in their own homes, and no history of bilateral hip 
fractures.  Recruitment letters were sent to more than 70,000 women and approximately 
19,000 (27%) responded.  A total of 4,169 women met all eligibility criteria and, of those, 
1,388 were randomized to the treatment arm and 2,781 to the control arm.  Participants 
in the intervention arm were mailed three SafeHip hip protectors and a leaflet describing 
methods to reduce the risk of hip fractures; the control arm received only the leaflet.  
Hip protector adherence and hip fracture outcomes were assessed by self-report via 
questionnaires mailed to all participants every six months.  Hip fractures were confirmed 
by the patient’s general practitioner.  General practitioners were also contacted during 
the two year follow-up period, if participants failed to respond to the mailed 
questionnaire, mainly to ascertain a hip fracture outcome.  During the two year follow-up 
period 39 hip fractures occurred in the treatment arm and 66 in the control arm – the 
intention-to-treat effect of hip protectors was an odds ratio (95% CI) of 1.17 (0.78,1.75).  
Self-reported adherence was low at 6 months (38%), and dropped even lower to 31% at 
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12 months.  As in the previous study by Birk et al, exposure and outcome were 
ascertained through self-report and hip fracture was confirmed by follow-up with the 
patient’s general practitioner.  A smaller validation study to evaluate the performance 
(i.e., sensitivity, specificity) of self-reported exposure and self-reported outcome in this 
setting would been valuable in evaluating the validity of the main study. 
 A cluster-randomized study of hip protectors was conducted by O’Halloran and 
colleagues83 in 146 nursing and residential homes in the greater Belfast area of 
Northern Ireland.  There were 40 homes (representing 1366 occupied beds) allocated to 
the intervention arm and 87 homes (representing 2751 occupied beds) in the control 
arm.  The intervention was a policy of providing SafeHip hip protectors to residents of 
the nursing homes and supporting the implementation of the policy through education 
and training.  Specifically, a nurse facilitator provided on-going support to the care staff 
and nursing home residents, including one hour workshops focusing on the risks and 
consequences of hip fractures, provision of manufacturer leaflets promoting the use of 
hip protectors, and provision of a videotaped presentation on the use of hip protectors.  
Adherence was assessed as a percentage of occupied beds using the hip protectors – 
initial acceptance was 37% but decreased to 20% by the end of the 72 week follow-up 
period.  There were 85 hip fractures in the intervention arm and 163 hip fractures in the 
control arm.  Using the total number of occupied beds to calculate the hip fracture rate 
in each arm of the study, the authors calculated a rate ratio (95% CI) of 1.05 (0.76, 
1.45) for the effect of hip protectors.  The negative finding in the study is not surprising, 
given the very low adherence over the course of the study. Also, there were 24 
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individuals in the control group who wearing hip protectors at the start of the study and 
they were not excluded from the analysis.  A study of this type may be useful at 
evaluating the effectiveness of hip protectors, but does not provide useful information 
about efficacy. 
 Another cluster-randomized study of hip protectors in Japan was reported by 
Koike and colleagues178 in an abstract.  There were a total of 76 aged-care facilities 
that were randomized in a 1:3 ratio to control and protector groups (the total number of 
facilities in each treatment arm was not indicated).  The intervention involved the 
provision of the SafeHip hip protector to women older than 65 years age that were 
mobile and at high risk for hip fractures.  In addition, monthly newsletters, posters, 
illustrated books, and visits by the research team were provided to improve the 
motivation of the nursing staff in the nursing homes. There were a total of 308 
participants in the treatment arm and they experienced 6 hip fractures during follow-up; 
the 306 participants in the control arm experienced 17 hip fractures.  The relative risk 
(95% CI) of hip fractures was 0.35 (0.14, 0.86), when comparing the treated group to 
the control group.  In the abstract, the authors indicated that 21 residents were excluded 
from the intention to treat analysis if they were bed-ridden, hospitalized or died during 
the 10 months of follow-up.  Such exclusion would invalidate the intention to treat 
analysis and it is not clear why the authors excluded these patients.  In addition, 
randomization occurred at the nursing home level in a 1:3 ratio, but the total number of 
residents in the two treatment arms is approximately equal.  This apparently conflicting 
information demands further explanation. 
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 Finally, a study by Kiel et al16 reported a multi-site randomized study of hip 
protectors in U.S. nursing homes.  This study was the one used for all analyses in this 
dissertation and is described in greater detail later.  Briefly, the study randomized 37 
nursing homes to have eligible residents wear hip protectors on either the left hip or 
right hip.  There were a total of 1042 participants who provided 676 person-years of 
follow-up.  A total of 21 hip fractures occurred in protected hips and 17 hip fractures 
occurred in unprotected hips.  The estimate for the effect of treatment was a rate ratio 
(95% CI) of 1.24 (0.65, 2.34).  Overall adherence was 74%. 
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Appendix 3 
The Effect of Hip Protectors in HIP PRO II 
 
 After termination of the first HIP PRO study, a second study of hip protectors was 
initiated using the FallGard FG-04 hip protector.  This hip protector was slightly more 
flexible than the hip protectors used in the first study and was composed of a dense (10 
lbs / ft3), 0.57 inch layer of polyvinyl chloride (PVN) rubber foam, backed by a softer 4 
lbs / ft3 PVN foam layer 0.18 inches thick.  The dimensions of this new hip protector 
were similar to the hip protectors used in the first study and utilized the same cotton 
Lycra undergarment.  In this second study, a total of 1445 residents contributed 1467 
hip years of observation between October 2004 and August 2006.  Some nursing home 
residents were switched to the new hip protector after termination of the first study, 
while 988 entirely new residents were also enrolled into the second hip protector study.  
As in the first study, participating residents had a mean age of 85 ± 8 years, and were 
primarily women (78%), white (86%), and had severe cognitive impairment (72%) 
(Table A3.1).  All but four nursing homes participating in the first study also contributed 
data to the second study; in addition, 18 new nursing homes were recruited.  These 
nursing homes were large (≥ 100 beds), mainly not-for-profit institutions (55%) (Table 
A3.2). 
 Our replication of the intent-to-treat (ITT) analysis, using pooled logistic 
regression, found a rate ratio of 1.13 (95% confidence interval (C.I.): 0.57, 2.27), 
comparing hip fractures in protected hips against hip fractures in unprotected hips.  As 
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with protectors in the first HIP PRO study, the ITT analysis for the second study 
suggests that the FallGard FG-04 hip protectors caused hip fractures, resulting in a non-
significant 13% increase in the incidence of hip fractures (compared to a 23% increase 
in the first study).  Employing the marginal structural models of Robins et al, we again 
constructed inverse probability of censoring weights (IPCWs) using a joint set of 
covariates that were determinants of non-adherence and hip fractures.  The set of 
covariates that resulted in the best-behaved weights (mean=1.00 ± 1.27) were the same 
as those used in the adherence correction analysis that was employed in the first HIP 
PRO study.  In the second study, after correcting for non-adherence with IPCWs, we 
found that constant exposure to the FallGard FG-04 hip protector resulted in a rate ratio 
of 0.75 (95% C.I.: 0.17, 3.36), when comparing hip fractures in protected hips against 
hip fractures in unprotected hips (Table A3.3). 
 Both HIP PRO studies, individually, had insufficient precision and were unable to 
definitively evaluate the outcome, when comparing protected and unprotected hips.  In 
both studies, the study design was the same, information on the clinical endpoint was 
evaluated by a hip fracture adjudication committee in a similar manner, and adherence 
was assessed in three weekly unannounced visits.  The only difference between the 
studies were the hip protectors used, the study time periods, and different (though 
overlapping) study populations and nursing homes.  Given the similarities between the 
studies and the few potential sources of heterogeneity, we proposed to combine the 
adherence-adjusted effect estimates from the two HIP PRO studies to estimate an 
overall effect.  We assessed the variability between the two studies using a fixed effects 
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model, where we assume that the variability is exclusively due to random variation, and 
used inverse variance to calculate the summary estimate. 
 Figure A3.1 shows a forest plot of the two HIP PRO studies, as well as the 
combined effect estimate.  There was no evidence of heterogeneity (χ2=0.09, 1 d.f., 
p=0.77).  The pooled data show a protective effect of hip protectors in preventing hip 
fractures, but the results remain statistically non-significant (RR=0.64, 95% CI: 0.23, 
1.82).  Even when we combine the adherence-corrected results from both HIP PRO 
studies, there were insufficient hip fractures to demonstrate a definitive protective effect 
of hip protectors.  Based on previous under-powered studies of hip protectors and the 
results from the current analysis, we recommend that researchers use conservative 
estimates of hip fracture incidence when designing randomized studies of hip 
protectors. 
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Table A3.1.  Selected Baseline Characteristics of Enrolled Residents (HIP PRO1 Study 
2) 
 
Characteristic 
Nursing Home Residents 
(N=1445)3 
Women 1126 (77.9) 
White2 1235 (85.5) 
Age, Mean (SD), year 84.5 (7.5) 
History of Osteoporosis2 319 (22.1) 
History of Fall in Last 30 Days2 424 (29.3) 
Marital Status2  
  Never 228 (15.8) 
  Married 256 (17.7) 
  Widowed 875 (60.6) 
  Divorced/Separated 86 (5.9) 
Cognitive Status2,4  
  Normal / Mild Impairment 197 (13.6) 
  Moderate Impairment 207 (14.3) 
  Severe Impairment 1041 (72.0) 
1Hip Impact Protection Project. 
2Missing data (<2% of total residents) replaced with mode of distribution. 
3Represents total N(%), unless otherwise noted 
4Cognitive status categories based on Short Blessed Test (SBT): normal / minimal 
impairment  (SBT = 0 – 8), moderate impairment (SBT = 9 – 19), severe impairment 
(SBT ≥ 20). 
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Table A3.2.  Nursing Home Characteristics (HIP PRO1 Study 2) 
 
Characteristic 
Nursing Home  
(N=51)2 
For Profit 23 (45.1) 
Total Number of Hospital Beds  
  < 100 Beds 5 (9.8) 
  100 – 149 Beds 22 (43.1) 
  150 – 199 Beds 17 (33.3) 
  >= 200 Beds 7 (13.7) 
NH Allows Hip Protectors to be Worn at 
    
 
  None 
 
11 (21.6) 
  Some 22 (43.4) 
  All 18 (35.3) 
1Hip Impact Protection Project. 
2Represents total N(%). 
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Table A3.3.  Intent-to-treat (ITT) and inverse probability of censoring weighted (IPCW) 
analysis of 1445 men and women randomized to wear hip protectors on either the left 
hip or the right hip (HIP PRO1 Study 2). 
Analysis Hip Status 
No. Hip 
Fractures 
No. Bi-
weeks 
Rate 
Ratio 
95% 
Confidence 
Interval 
ITT Protected 17 38129 1.13 (0.57, 2.27) 
 Unprotected 15 38129 1 - 
IPCW32 Protected 1.9 6415 0.75 (0.17, 3.36) 
 Unprotected 15 38129 1 - 
1Hip Impact Protection Project. 
2Individuals censored in first bi-week in which adherence is less than 75%. 
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Figure A3.1. Forest plot of rate ratios for incidence of hip fractures in two hip protector 
studies conducted by the Hip Impact Protection Project (HIP PRO) 
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Appendix 4 
A Simulation Exercise Comparing Results from an Intention-to-Treat (ITT) 
Analysis, an Instrumental Variable (IV) Analysis, and an Analysis Using Structural 
Nested Models (SNMs) 
 
Briefly, we created J=1000 trials, each comprised of I=1000 patients, for each of 
K=18 simulation scenarios.  The K scenarios varied the composition of the study 
population, which we conceptualized as being comprised of four types: ‘would-be 
compliers,’ ‘always-takers,’ ‘never-takers,’ and ‘defiers.’ Specifically, the first six 
scenarios used study populations comprised of only ‘would-be compliers’ and ‘always-
takers’; scenarios 6-12 used study populations comprised only of ‘would-be compliers’ 
and ‘never-takers’; scenarios 13-18 had only ‘would-be compliers’ and ‘defiers.’  Within 
each trial j, a simulated data record for each individual i was comprised of three 
variables X, Z, and T. For context, X represented the randomization variable and was 
generated with a Bernoulli random variable and took values of 0 and 1, with probability 
0.5, and Z represented treatment actually received and was dependent on an 
individual’s compliance ‘type’ (e.g., for a ‘would-be complier’ treatment received, Z, is 
equal to treatment assigned, X, while for a defier treatment received is equal to the 
opposite of treatment assigned). Finally, T was a time-to-event. Note that the actual 
effect of treatment on T depends on treatment received, not on treatment assignment 
(i.e., the exclusion restriction holds). For the ITT analysis, we use a linear regression 
model to estimate the effect of randomization, X, on the time to an event. A linear model 
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is appropriate as there was no censoring.  In contrast, we implement a two-stage least 
squares algorithm for the IV analysis by first regressing X on Z and then regressing T on 
the predicted value of X obtained from the first linear regression. Finally, we use g-
estimation (i.e., logistic regression coupled with a grid search), as has been previously 
described, to estimate the factor by which assignment to treatment extends or contracts 
the average time to the outcome. 
 The results of the simulations are presented next.  The simulations confirm some 
of the expected findings based on the theory behind the ITT, IV, and SNM approaches. 
First, note that in each scenario of the first set (i.e., 1-6), as the proportion of non-
adherent participants increases, the ITT effect estimate is biased further toward the null 
(the effect estimate should be compared with the ‘truth,’ which is an effect on the risk 
difference scale of 2). A non-adherent participant can be an ‘always-taker,’ a ‘never-
taker,’ or a ‘defier’.  Also, in the first two sets of scenarios, the adherence-correction 
methods only work when there is a nonzero group of adherent patients. When there are 
no adherent patients, the confidence intervals of the adherence corrected effect 
estimates become untenable. Finally, in the third set of scenarios (i.e., 13-18), the IV 
and SNM methods also fail to correct for non-adherence when there exist any defiers. 
Neither adherence-corrected method is able to recover the true risk difference, 
regardless of the proportion of participants that are ‘defiers’ (i.e., participants who 
always do the opposite of what they are assigned).  Fortunately, individuals who 
perversely do the opposite of what they are assigned should be rare in real world 
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settings and the assumption of no defiers should readily be met.  For the remainder of 
the discussion, we focus on the first two sets of scenarios (i.e., 1-12). 
 Regardless of whether a non-adherent participant is an ‘always-taker’ or a 
‘never-taker’, the IV and SNM methods are always able to recover the true effect of 
treatment, as long as there are some ‘would-be compliers’ in the study population. Note, 
however, that the precision of the effect estimates is reduced as the proportion of non-
adherent participants increase. Recall that our original purpose for undertaking the 
simulation exercise was to determine the target population for an SNM analysis. In this 
simulation, under the assumptions outlined earlier, the target population, for both the IV 
method and the SNM method, appears to be the same, namely the ‘would-be 
compliers.’ This similarity in the target population is only indirectly confirmed, however, 
based on the fact that the adherence-corrected effect estimates are similar. As noted 
previously, only a derivation mapping the estimand for the IV method to the estimand for 
the SNM method can resolve the question of whether the target population for an SNM 
method is the same as the IV method.  While questions remain, this simulation exercise 
reveals that both the IV method and the SNM method appropriately correct for non-
adherence.  Also, on the risk difference scale, both methods produce similar effect 
estimates
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